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ABSTRACT 
Tometich, Danielle B. M.S., Purdue University, August 2016. Symptom Severity and 
Importance in Metastatic Breast Cancer Survivors: An Examination of Cognitive 
Complaints and Related Symptoms. Major Professor: Catherine Mosher. 
 
 
 
Cognitive changes associated with cancer and its treatment have been well documented.  
However, the majority of research on cognitive symptoms in cancer has been conducted 
with early-stage breast cancer patients or survivors in remission.  Little is known about 
cognitive symptoms in patients with late-stage or metastatic cancers.  To address this gap 
in the literature, this study examines cognitive and related symptoms among metastatic 
breast cancer patients enrolled in a parent study of perceptions of symptom importance 
and interference.  Eighty metastatic breast cancer patients were recruited from the Indiana 
University Simon Cancer Center to participate in this cross-sectional telephone interview 
study.  The interview consisted of self-report measures, including measures of symptom 
severity, distress, and the importance of seeing improvement in specific symptoms post-
treatment.  I hypothesized that cognitive complaints would cluster with fatigue, sleep 
disturbance, depressive symptoms, anxiety, and pain.  This hypothesis was tested using 
cluster analysis and was partially supported.  Cognitive complaints were found to cluster 
with fatigue, sleep disturbance, depressive symptoms, and anxiety, but not pain.  In 
addition, the extent to which ratings of symptom importance for cognitive symptoms 
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differed from those of other symptoms (i.e., pain, fatigue, sleep problems, depressive 
symptoms, anxiety, nausea, lymphedema, hot flashes, and neuropathy) was explored 
using ANOVA and Tukey’s HSD tests.  Cognitive complaints were rated as significantly 
more important than anxiety, depressive symptoms, neuropathy, swelling, nausea, and 
hot flashes.  Importance ratings for cognitive complaints, pain, fatigue, and sleep 
problems were not significantly different.  Developing patient-centered treatment 
approaches that take into account symptom clustering and patients’ treatment priorities 
may increase treatment adherence and optimize healthcare quality.  
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
Cognitive changes have been associated with cancer and its treatment in early-stage 
breast cancer patients (Ahles, Schagen, & Vardy, 2012; Hurria, Somlo, & Ahles, 2007; 
Ono et al., 2015), but a paucity of research has examined cognitive changes in patients 
with metastatic cancers.  Cognitive difficulties are typically viewed as a survivorship 
issue affecting functional capacity (Hede, 2008; Von Ah, 2015).  The majority of 
research in this area has been conducted with early-stage breast cancer patients and 
survivors in remission due to their large numbers and high likelihood of long-term 
survival (Ahles, Schagen, et al., 2012; Newman, 2009; Von Ah, 2015).  It is estimated 
that 2.9 million women were living with a breast cancer diagnosis of any stage in the 
United States in 2012 (Howlader et al., 2015), and 17-75% of breast cancer survivors 
have some degree of cognitive dysfunction (Ahles, Root, & Ryan, 2012; Von Ah, 2015).  
Survivorship issues, including cognitive changes, are becoming increasingly 
relevant for patients with late-stage disease as recent advances in treatment have 
increased longevity (Mayer, 2010; Reed, Simmonds, Haviland, & Corner, 2012).  After a 
diagnosis of metastatic breast cancer, survival can range from a few months to more than 
five years, and the median survival time is approximately three years (Smerage et al., 
2014).  Between 2005-2011, 5-year survival rates for metastatic breast cancer were 
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estimated to be 25.9% (Howlader et al., 2015).  Thus, metastatic breast cancer patients 
may live for years with cognitive impairment which affects their daily activities and 
quality of life, but little is known regarding their cognitive symptoms.  This study begins 
to address this gap by examining cognitive symptoms’ relationship to other symptoms in 
this population.  In addition, patient ratings of the importance of seeing improvement in 
cognitive symptoms following symptom-focused treatment were compared to those for 
other common symptoms.  
First, I will discuss the evidence for a relationship between cancer and its 
treatment and cognitive symptoms and current theoretical models of this relationship.  
Next, I will describe the available literature on cognitive symptoms in metastatic breast 
cancer patients.  Finally, I will provide a rationale for characterizing symptom clusters 
and patient perceptions of symptom importance in cancer patients.  Following this 
review, I will present my hypotheses, study methods, and results and discuss the 
implications and limitations of my findings.  
1.2   Cognitive Symptoms in Cancer 
History, terminology, and definitions.  Medical and psychological scientists 
have known about the association between chemotherapy treatments for cancer and 
cognitive impairment for more than 40 years (Silberfarb, 1983; Weiss, Walker, & 
Wiernik, 1974).  The first reviews exploring the neurotoxic effects of chemotherapy were 
published in the 1970s, and they acknowledged neurological symptoms such as 
somnolence and encephalopathy in cancer patients with primary central nervous system 
(CNS) disease or CNS metastases (Pochedly, 1977; Weiss et al., 1974).  Shortly 
thereafter, reviews described the possibility of CNS toxicities due to cancer treatment in 
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patients without CNS disease (Allen, 1978; Silberfarb, 1983).  The colloquial terms 
“chemobrain” and “chemofog” were coined in the 1990s to describe the cognitive 
symptoms that appeared to be related to chemotherapy (Ahles, Schagen, et al., 2012).  It 
later became apparent that numerous factors besides chemotherapy can contribute to 
cognitive symptoms; thus, the terms “chemobrain” and “chemofog” have been replaced 
with “cancer- or cancer treatment-associated cognitive change” (Hurria et al., 2007). 
The terminology for describing cancer patients’ cognitive performance on 
neuropsychological tests is also controversial.  The term “cognitive impairment” is often 
used in cross-sectional studies comparing patients treated with chemotherapy to non-
chemotherapy controls, and the term “cognitive decline” is used in longitudinal studies of 
chemotherapy-treated patients (Ono et al., 2015).  Ahles and colleagues (2008) question 
whether it is appropriate to label cognitive problems in cancer patients as “impairment” 
when they are typically subtle and often within the normal range.  Instead, these 
researchers describe the cognitive deficits found in a subset of their study participants as 
“lower than expected cognitive performance” (Ahles et al., 2008, p. 144).    
Currently, little consensus exists regarding the definition of cognitive 
impairment/decline in cancer populations, and clinically significant cognitive 
impairment/decline has no established cut-off point or statistical convention (Ono et al., 
2015).  Ahles and colleagues (2008) define “lower than expected cognitive performance” 
as two neurocognitive domains that are 1.5 standard deviations below the mean of 
published norms or one domain that is 2 standard deviations below the mean.  Cognitive 
decline in longitudinal studies has often been defined as a 1 to 2 standard deviation 
decrease in scores on one or more cognitive domains from pre- to post-chemotherapy 
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(Hurria et al., 2006; Ono et al., 2015; Shilling, Jenkins, Morris, Deutsch, & Bloomfield, 
2005; A. Stewart et al., 2008; Vearncombe et al., 2009).  Cognitive impairment in some 
cross-sectional studies has been defined as 2 standard deviations below the mean 
performance of a healthy comparison group or published norm (de Ruiter et al., 2011; 
Deprez et al., 2011; Donovan et al., 2005; Ono et al., 2015; Schagen, Hamburger, Muller, 
Boogerd, & van Dam, 2001; Schagen et al., 1999; Schilder et al., 2009).  Cognitive 
impairment has also been classified by degrees from mild (1 standard deviation below the 
norm) to moderate impairment (2 standard deviations below the norm) (Hermelink et al., 
2007; Ono et al., 2015).  
Evidence suggests that, in general, breast cancer patients treated with 
chemotherapy have worse performance on objective cognitive tests than control groups, 
but impairment is not consistently found in specific neurocognitive domains (Jim et al., 
2012; Ono et al., 2015).  A recent meta-analysis examined cross-sectional and 
prospective longitudinal studies of cognitive functioning among non-metastatic breast 
cancer patients treated with adjuvant chemotherapy (Ono et al., 2015).  Analyses of 
cross-sectional data revealed statistically significant cognitive impairment in five of the 
eight examined neurocognitive domains: processing speed (d = -0.25), executive function 
(d = -0.19), attention (d = -0.16), motor function (d = -0.16), and short-term memory (d = 
-0.15).  Effect sizes were non-significant for the domains of language, long-term 
memory, and visuospatial function (Ono et al., 2015).  These results are partially 
consistent with those of prior meta-analyses (see Table 1).  Two of the four prior meta-
analyses found significant deficits in executive function (Jansen, Miaskowski, Dodd, 
Dowling, & Kramer, 2005; A. Stewart, Bielajew, Collins, Parkinson, & Tomiak, 2006), 
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one found a significant deficit in processing speed (Jansen et al., 2005), and another 
found significant deficits in motor speed, and short-term memory (A. Stewart et al., 
2006).  However, three of the four prior meta-analyses also found significant deficits in 
language (Falleti, Sanfilippo, Maruff, Weih, & Phillips, 2005; Jim et al., 2012; A. Stewart 
et al., 2006), two found significant deficits in spatial function (Falleti et al., 2005; Jim et 
al., 2012), and one found significant deficits in long-term memory (A. Stewart et al., 
2006). 
Findings are also inconsistent with respect to moderators of cognitive 
performance in breast cancer patients post-chemotherapy.  An earlier meta-analysis of 
cross-sectional studies found that age and time since chemotherapy treatment moderated 
the magnitude of cognitive impairment post-treatment (Falleti et al., 2005), whereas more 
recent meta-analyses did not replicate these findings (Jim et al., 2012; Ono et al., 2015).  
Instead, the type of control group and level of education were significant moderators (Jim 
et al., 2012; Ono et al., 2015).  Specifically, in cross-sectional studies, breast cancer 
patients who had received chemotherapy had significant cognitive impairment when 
compared to healthy controls, but not when compared to breast cancer patients without a 
history of chemotherapy treatment (Ono et al., 2015).  In addition, breast cancer patients 
with fewer years of education showed a greater degree of cognitive impairment (Ono et 
al., 2015).  Age was also a significant moderator of cognitive change in a meta-analysis 
of prospective longitudinal studies, with older age being associated with greater cognitive 
decline post-chemotherapy (Ono et al., 2015). 
Another key finding from prospective longitudinal studies is that breast cancer 
patients show improved cognitive function in certain domains from pre- to post-
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chemotherapy (Falleti et al., 2005; Ono et al., 2015; Wefel, Lenzi, Theriault, Davis, & 
Meyers, 2004).  One meta-analysis of these studies found that long-term memory 
significantly improved following chemotherapy (d = 0.41); however, other cognitive 
domains did not significantly change, with effect sizes ranging from d = -0.29 for 
visuospatial function to d = 0.26 for language (Ono et al., 2015).  Conversely, an older 
prospective longitudinal study of breast cancer patients found improved attention (d = 
1.09), executive function (d = 0.39), memory (d = 0.36), spatial ability (d = 0.31), and 
motor function (d = 0.11) post-chemotherapy (Falleti et al., 2005; Wefel et al., 2004).  
Researchers have proposed multiple explanations for breast cancer patients’ 
improved cognitive function from pre- to post-chemotherapy.  One explanation focuses 
on psychological factors (e.g., anxiety, depressive symptoms) associated with a cancer 
diagnosis and impending treatment that may affect cognitive performance; specifically, 
performance is expected to improve after chemotherapy as patients psychologically 
adjust to their medical situation (Falleti et al., 2005; Ono et al., 2015).  Thus, pre-
treatment assessments of cognitive functioning may not provide an accurate estimate of 
premorbid functioning, complicating examination of post-chemotherapy changes in 
cognition.  This theory is supported by findings that greater pretreatment worry in breast 
cancer patients is associated with altered brain activation on an fMRI, worse objective 
performance in verbal working memory, and subjective cognitive dysfunction (Berman et 
al., 2014).  Alternatively, improvement in cognitive performance from pre- to post-
chemotherapy may be due to practice effects, although this is less likely because studies 
regularly control for practice effects with alternative test forms or statistical controls 
(Falleti et al., 2005; Ono et al., 2015).  Lastly, meta-analyses of cognitive impairment in 
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breast cancer patients treated with adjuvant chemotherapy have not separately analyzed 
results from recognition and recall tests (Falleti et al., 2005; Jansen et al., 2005; Jim et al., 
2012; Ono et al., 2015; A. Stewart et al., 2006).  Recognition memory tests are not 
sensitive to subtle cognitive deficits (Welsh, Butters, Hughes, Mohs, & Heyman, 1992); 
thus, collapsing recall and recognition memory performance into one cognitive domain 
may be underestimating memory deficits and limit researchers’ ability to draw accurate 
conclusions from the data (F.W. Unverzagt, personal communication, March 17, 2015). 
 Models of cognitive symptoms in cancer.  Cognitive impairment in cancer 
patients is most commonly associated with adjuvant chemotherapy treatments for breast 
cancer (Bender et al., 2006; Schagen et al., 1999; van Dam et al., 1998), but it has also 
been associated with endocrine or hormone therapy for breast cancer (Jenkins, Shilling, 
Fallowfield, Howell, & Hutton, 2004; Zwart, Terra, Linn, & Schagen, 2015) and 
radiation therapy for primary CNS cancer or CNS metastases (Dietrich, Monje, Wefel, & 
Meyers, 2008).  Furthermore, some studies have found cognitive impairment in breast 
cancer patients after surgery, but before any hormone, radiation, or chemotherapy 
treatment (Ahles et al., 2008; Berman et al., 2014).  This suggests that surgery, the 
disease, or psychological reactions to the disease may be sufficient precipitants of 
cognitive sequelae.  To date, no systematic review has been conducted to compare the 
cognitive effects of different cancer treatments.  Sufficient data are not available for this 
analysis because many cancer patients receive multiple treatment types, some of which 
are concurrently administered (Hurria et al., 2007).   
A number of models have been proposed to characterize the multiple, interactive 
factors that may result in cognitive symptoms in cancer patients (Ahles, Root, et al., 
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2012; Mandelblatt et al., 2013; Meyers & Perry, 2008; Wefel, Collins, & Kayl, 2008).  
One conceptual model of cognitive dysfunction in cancer is analogous to the interaction 
between soil, seed, and pesticides (Figure 1).  The soil represents host factors (e.g., 
genetics, cognitive reserve), the seed, disease-related factors (e.g., cytokines, tumor 
genetic mutations), and the pesticides, treatment-related factors (e.g., chemotherapy, 
radiation, hormonal therapy) (Meyers & Perry, 2008).  As soil, seed, and pesticides all 
contribute to the health of a plant, so do host, disease, and treatment factors all contribute 
to the cognitive health of a cancer patient.  
Host factors are generally present prior to cancer treatment and include age, 
genetics, cognitive reserve, and psychological factors.  Older age is associated with 
greater cognitive decline in prospective longitudinal studies of breast cancer patients 
treated with chemotherapy (Bender et al., 2006; Collins, Mackenzie, Stewart, Bielajew, 
& Verma, 2009; Debess, Riis, Engebjerg, & Ewertz, 2010; Falleti et al., 2005; Hermelink 
et al., 2007; Hurria et al., 2006; Jansen, Cooper, Dodd, & Miaskowski, 2011; Jenkins et 
al., 2006; Ono et al., 2015; Shilling et al., 2005; A. Stewart et al., 2008; Vearncombe et 
al., 2009; Wefel et al., 2004).  Genetic factors related to cognitive decline in aging and 
cancer include apolipoprotein E (APOE) and catechol-o-methyl transferase (COMT) 
(Ahles, Root, et al., 2012; Ahles et al., 2003; Harris & Deary, 2011; Small et al., 2011).  
Genetic and environmental variables (e.g., education, occupation) contribute to cognitive 
reserve, or the capacity for cognitive function (Ahles et al., 2010; Stern, 2002).  People 
with lower levels of cognitive reserve are at higher risk for neurodegenerative diseases 
such as Alzheimer’s disease (Ahles et al., 2010; Whalley, Deary, Appleton, & Starr, 
2004) and are more susceptible to poorer cognitive outcomes after exposure to 
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neurotoxins compared to those with higher levels of cognitive reserve (Ahles et al., 2010; 
Bleecker, Ford, Celio, Vaughan, & Lindgren, 2007).  Age, cognitive reserve, and receipt 
of chemotherapy were found to have an interactive effect on cognitive functioning in 
non-metastatic breast cancer patients; specifically, older patients who had lower levels of 
cognitive reserve and had been exposed to chemotherapy were impaired on processing 
speed compared to other groups (e.g., younger patients, patients with higher levels of 
cognitive reserve, patients not exposed to chemotherapy, healthy controls) (Ahles et al., 
2010).  Processing speed was the only examined outcome because previous research has 
found it to be sensitive to the effects of cancer treatment (Ahles et al., 2010; Correa & 
Ahles, 2008). 
The host factors of anxiety, depression, fatigue, and sleep disturbance have been 
inconsistently associated with cognitive symptoms in cancer patients (Ahles & Saykin, 
2001, 2002; Ono et al., 2015; Schagen, Muller, Boogerd, & van Dam, 2002; Valentine & 
Meyers, 2001; Vearncombe et al., 2009).  These factors are more often related to 
subjective cognitive complaints than objective cognitive impairment (Jim et al., 2012; 
Ono et al., 2015; van Dam et al., 1998).  These four constructs are frequently 
characterized as “psychological factors” in research on cognitive difficulties in cancer 
and are either statistically or methodologically controlled (Ahles, Root, et al., 2012; 
Hurria et al., 2007; Ono et al., 2015).  Other researchers argue that they are also 
symptoms of cancer and its treatment (Miaskowski, Dodd, & Lee, 2004).  
Disease-related factors possibly involved in cognitive change in cancer patients 
include genetic mutations and DNA damage, neurotoxic cytokines, and disease stage 
(Ahles, Root, et al., 2012; Meyers & Perry, 2008).  Even prior to chemotherapy, it is 
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estimated that 20-30% of non-metastatic breast cancer patients have some degree of 
cognitive impairment compared to age- and education-adjusted norms, and this does not 
appear to be due to depressive symptoms, anxiety, fatigue, or surgery (Ahles, Root, et al., 
2012; Ahles et al., 2008).  Ahles and colleagues (2012) have presented two non-mutually 
exclusive hypotheses for direct effects of disease-related factors on cognitive symptoms 
in cancer: 1) there may be common risk factors for breast cancer and age-related 
cognitive decline; and 2) the biology of cancer affects cognitive performance.  Both of 
these hypotheses have correlational support.  Genetic mutations preventing repair of 
damaged DNA have been associated with increased risk for developing breast cancer, 
and deficient DNA repair has also been associated with neurodegenerative disorders such 
as Alzheimer’s disease and Parkinson’s disease (Ahles & Saykin, 2007).  
Regarding the second hypothesis, one way that the biology of cancer can impact 
cognition is through an inflammatory response that activates neurotoxic cytokines (Ahles, 
Root, et al., 2012; Ahles & Saykin, 2007).  Cytokine dysregulation has been associated 
with neurodegenerative disorders, cognitive disorders, fatigue, and depression (Ahles & 
Saykin, 2007).  Recent findings show a significant relationship between elevated 
cytokine levels and poorer cognitive performance in breast cancer patients prior to 
treatment after controlling for other factors related to cognitive decline, such as age, 
education, and mood (Patel et al., 2015).  
Cancer stage is another disease-related factor that may contribute to cognitive 
impairment.  One study found that prior to chemotherapy, breast cancer patients with 
invasive disease were more likely than breast cancer patients with noninvasive disease to 
have decrements in cognitive performance compared to published norms, and these 
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patient groups did not differ on depressive symptoms, anxiety, or fatigue (Ahles et al., 
2008).  Unfortunately, disease stage is often confounded with treatment type in 
prospective longitudinal studies examining cognitive changes in cancer, which limits the 
conclusions that may be drawn (McDonald, Conroy, Ahles, West, & Saykin, 2010).  
Treatment-related factors that may contribute to cognitive changes in cancer 
patients include chemotherapy, endocrine or hormone therapy, and radiation therapy.  
Evidence suggests that chemotherapy may cause changes in brain structure for at least a 
subgroup of cancer patients (Ahles, Root, et al., 2012; Hurria et al., 2007; Ono et al., 
2015; A. Stewart et al., 2006).  For example, imaging studies with breast cancer patients 
showed decreased grey matter in frontal, temporal, and cerebellar regions and the right 
thalamus at one month post-chemotherapy, whereas non-chemotherapy treated patients 
only showed decreased grey matter in cerebellar regions and healthy controls showed no 
significant structural changes (McDonald et al., 2010).  These structural changes have not 
been associated with objective cognitive impairment, although chemotherapy-treated 
patients showed a non-significant decline in high-load working memory performance 
from baseline to one month post-chemotherapy along with compensatory hyperactivation 
in frontal cortices on fMRI (McDonald, Conroy, Ahles, West, & Saykin, 2012).  
Chemotherapy-treated patients showed only partial recovery of grey matter density at 1-
year follow-up (McDonald et al., 2010).  The mechanism by which chemotherapy affects 
cognition is still unknown (Ahles, Root, et al., 2012), although there are several theories.  
Animal models suggest that chemotherapy agents that cross the blood-brain barrier can 
reduce blood flow to the brain, cause DNA and white matter damage, inhibit the growth 
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of neurons in the hippocampus, and decrease activation in the hypothalamic-pituitary-
adrenal (HPA) axis (Ahles, Root, et al., 2012; Seigers & Fardell, 2011).  
Knowledge of the effects of hormonal and radiation therapy on cognition in 
cancer patients has been growing in recent years.  Regarding hormonal therapy, results of 
several randomized trials suggest that tamoxifen is associated with cognitive impairment 
in breast cancer patients, whereas aromatase inhibitors (e.g., exemestane, anastrozole) are 
not (Zwart et al., 2015).  Although radiation therapy to the brain and spinal cord has long 
been associated with cognitive and neurological symptoms in cancer patients (Crossen, 
Garwood, Glatstein, & Neuwelt, 1994; Dietrich et al., 2008; Keime-Guibert, Napolitano, 
& Delattre, 1998; Perry & Schmidt, 2006), emerging evidence suggests non-CNS 
radiation therapy is also associated with objective and subjective cognitive change in 
patients with several cancer types (Geinitz et al., 2001; Janaki et al., 2010; Jim et al., 
2009; Kohli et al., 2007; Marchand et al., 2010; Noal et al., 2011; Phillips et al., 2012; 
Quesnel, Savard, & Ivers, 2009; Schagen et al., 2008; Shibayama et al., 2014).  However, 
the evidence is inconsistent: one study found no relationship between radiation therapy 
and cognitive complaints (Browall et al., 2008), a few showed rapid reductions in 
cognitive complaints after treatment (Geinitz et al., 2001; Janaki et al., 2010; Marchand 
et al., 2010), and others found objective and subjective cognitive symptoms lasting 
months to years after treatment (Jim et al., 2009; Kohli et al., 2007; Noal et al., 2011; 
Phillips et al., 2012; Quesnel et al., 2009; Schagen et al., 2008; Shibayama et al., 2014).  
Methodological differences may explain some of the inconsistent findings (Shibayama et 
al., 2014).  Some studies only assessed subjective cognitive complaints (Browall et al., 
2008; Geinitz et al., 2001; Janaki et al., 2010; Kohli et al., 2007; Marchand et al., 2010), 
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whereas others also measured objective cognitive performance (Jim et al., 2009; Noal et 
al., 2011; Phillips et al., 2012; Quesnel et al., 2009; Schagen et al., 2008; Shibayama et 
al., 2014).  Control groups also differed (Shibayama et al., 2014); some studies only used 
healthy comparison groups (Jim et al., 2009; Phillips et al., 2012; Quesnel et al., 2009), 
and several did not include a comparison group (Browall et al., 2008; Geinitz et al., 2001; 
Janaki et al., 2010; Marchand et al., 2010; Noal et al., 2011).  Shibayama and colleagues 
(2014) explored a possible mechanism for the effect of non-CNS radiation therapy on 
cognition in early-stage breast cancer patients.  Specifically, elevated levels of 
proinflammatory cytokine IL-6 were found to significantly mediate the relationship 
between receipt of radiation treatment and worse cognitive performance.  
 While some models describe potential contributors to cognitive symptoms in 
cancer patients, other models describe the trajectory of cognitive changes.  The phase 
shift hypothesis assumes stable decrements in cognition in cancer patients compared to 
healthy individuals without a cancer history, such that cognitive dysfunction in cancer 
patients parallels normal aging (Figure 2) (Ahles, Root, et al., 2012; Mandelblatt et al., 
2013).  Conversely, the accelerated aging hypothesis suggests that the slope of cognitive 
decline over time is steeper for cancer patients compared to healthy individuals without a 
cancer history (Figure 2) (Ahles, Root, et al., 2012; Mandelblatt et al., 2013).  Further 
longitudinal research is needed to determine which hypothesis is correct, or if both are 
correct, but for different patient populations.  For example, it is possible that younger 
patients with greater cognitive reserve show a phase shift pattern, whereas older patients 
with less cognitive reserve show accelerated aging (Ahles, 2012). 
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Ahles and colleagues (2012) hypothesize that aging and cancer affect cognition in 
two ways: 1) the initial impact of cancer treatments has a domino effect on several 
biological systems that results in progressive cognitive decline with aging, or 2) a 
treatment might not result in enough initial biological damage to affect cognition 
immediately, but there may be a delayed effect with increasing age.  These patterns are 
supported by evidence from a longitudinal study of non-metastatic breast cancer patients 
treated with chemotherapy (Wefel, Saleeba, Buzdar, & Meyers, 2010).  The following 
patterns of cognitive functioning were found: 1) cognitive decline immediately post-
treatment and continued decline one year post-treatment; 2) cognitive decline 
immediately post-treatment and stable cognitive functioning at one year; and 3) no 
cognitive decline immediately post-treatment and new cognitive decline at one year post-
treatment (Ahles, Root, et al., 2012; Wefel et al., 2010).  Clinical, mood, and 
demographic variables did not significantly differentiate patients with acute or late 
cognitive decline, but there were non-significant trends suggesting that older age and 
baseline cognitive impairment may be risk factors for acute and late decline (Wefel et al., 
2010).  The authors suggested that diminished cognitive reserve pre-treatment may 
contribute to late cognitive decline or prevent recovery from acute impairment.  
To summarize, evidence suggests that host, disease, and treatment factors are 
directly and indirectly associated with cognitive impairment in cancer patients (Ahles, 
Root, et al., 2012; Ahles & Saykin, 2007; Ahles et al., 2003; Berman et al., 2014; Conroy 
et al., 2013; McDonald et al., 2010; Meyers & Perry, 2008; Ono et al., 2015; Patel et al., 
2015; Zwart et al., 2015).  However, a number of gaps in this literature remain, especially 
with respect to the impact of psychological factors and disease variables on cognition.  
15 
 
 
The model of trajectories of aging and cognitive decline in cancer is theoretically sound 
and has support from one longitudinal study (Ahles, Root, et al., 2012; Mandelblatt et al., 
2013; Wefel et al., 2010).  Taken together, models of cognition in cancer inform research 
and treatment by suggesting testable pathways by which various factors may impact 
cognition within the broader context of aging (Ahles, Root, et al., 2012; Mandelblatt et 
al., 2013; Meyers & Perry, 2008).  
Cognitive complaints in cancer.  Although substantial evidence supports 
cognitive change associated with cancer and its treatment (Ahles, Root, et al., 2012; 
Hurria et al., 2007; Ono et al., 2015; Von Ah, 2015), the relationship between objective 
and subjective cognitive impairment in cancer patients is less clear.  Objective cognitive 
impairment as measured by neuropsychological tests is often found to have little to no 
correlation with subjective cognitive impairment or cognitive complaints (Ahles & 
Saykin, 2002; Hurria et al., 2007; Schagen et al., 2002; Schagen et al., 1999).  One 
explanation for this finding is that brief neuropsychological tests commonly used in 
research are not sufficiently sensitive to detect the subtle cognitive deficits associated 
with cancer and its treatment (Hurria et al., 2007).  An fMRI neuroimaging study found 
support for this hypothesis; during a working memory task, breast cancer patients did not 
show objective impairment compared to controls, yet they had hyperactivation of brain 
areas associated with executive function (McDonald et al., 2012).  These findings suggest 
that the brains of breast cancer patients engage in compensatory processes (McDonald et 
al., 2012); thus, patients may find tasks to be more effortful while showing little to no 
objective impairment.  Some researchers have concluded that cognitive complaints 
represent subtle changes in cognitive function that should be a focus of research and 
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clinical efforts (Pullens, De Vries, Van Warmerdam, Van De Wal, & Roukema, 2013; 
Von Ah & Tallman, 2015).  
 An alternative explanation for the small to non-existent correlation between 
subjective and objective cognitive impairment is that cognitive complaints are more 
indicative of psychological distress than cognitive dysfunction (Jansen, 2013; Jenkins et 
al., 2006; Kibiger, Kirsh, Wall, & Passik, 2003; Poppelreuter et al., 2004; Pullens, De 
Vries, & Roukema, 2010; Shilling & Jenkins, 2007; Von Ah & Tallman, 2015).  Multiple 
studies have found a significant, moderate to strong positive relationship between 
depressive symptoms and cognitive complaints (Cimprich, So, Ronis, & Trask, 2005; 
Jenkins et al., 2006; Pullens et al., 2013; Shilling & Jenkins, 2007; Weis, Poppelreuter, & 
Bartsch, 2009).  Some researchers have suggested that depressive symptoms are more 
likely to impair cognitive functioning in everyday life than during controlled 
neuropsychological testing; thus, cancer patients with depressive symptoms may report 
difficulty performing routine tasks while still performing normally on objective tests 
(Shilling & Jenkins, 2007; Weis et al., 2009).  Others argue that although psychological 
factors may directly increase cognitive complaints, they may also contribute to subtle 
deficits in cognitive function that may not be detectable with objective tests (Jean-Pierre, 
Johnson-Greene, & Burish, 2014).  Indeed, depression has been associated with structural 
and functional changes in brain regions responsible for attention and memory (Bird & 
Burgess, 2008; Jean-Pierre et al., 2014; Milne, MacQueen, & Hall, 2012; Sievers et al., 
2012).  Depression has also been associated with proinflammatory cytokines such as 
interleukin (IL)-1 and tumor necrosis factor (TNF)-alpha (Schiepers, Wichers, & Maes, 
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2005), which have been related to objective and subjective cognitive symptoms in cancer 
patients (Ganz et al., 2013; Seruga, Zhang, Bernstein, & Tannock, 2008). 
Subjective cognitive function may also be influenced by patients’ expectations.  
One study found that breast cancer patients who were primed with a letter explaining 
cognitive changes associated with cancer and its treatment were more likely to report 
cognitive complaints during an interview about their symptoms compared to those who 
did not receive the letter (Schagen, Das, & van Dam, 2009).  The priming effect was 
present for both patients who had and had not been previously treated with 
chemotherapy, although it was stronger for patients with no prior chemotherapy treatment 
(Schagen et al., 2009).  This discrepant priming effect may be explained by ceiling 
effects for the chemotherapy-treated patients.  That is, chemotherapy-naive patients may 
be more vulnerable to priming because they are unable to draw upon personal experience 
with effects of chemotherapy (Schagen et al., 2009).  The same group of researchers later 
conducted a similar priming study that produced comparable expectancy effects with 
respect to cognitive complaints and objective test performance; however, the effects were 
stronger for chemotherapy-treated patients than chemotherapy-naïve patients (Schagen, 
Das, & Vermeulen, 2012).  Prior knowledge of the possible effect of chemotherapy on 
cognition may be important for priming to take place; only about half of patients in the 
first study had pre-study knowledge of the relationship between chemotherapy and 
cognition, whereas the majority of the patients in the second study had that knowledge 
(Schagen et al., 2012).  The researchers concluded that providing information about 
cognitive symptoms to patients treated with chemotherapy induces a stereotype threat 
which can affect both objective and subjective cognitive outcomes (Schagen et al., 2012). 
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Although cognitive complaints have been variously characterized as subtle 
cognitive deficits, psychological distress, and expectancy effects, assessment of these 
complaints uniquely informs our understanding of patients’ experiences.  Some 
researchers argue that perceived cognitive impairment is as important to assess as 
objective impairment due to its association with patients’ functional status and quality of 
life (Hutchinson, Hosking, Kichenadasse, Mattiske, & Wilson, 2012; Shilling & Jenkins, 
2007).  Greater cognitive complaints are associated with greater depressive symptoms, 
anxiety, and fatigue and poorer quality of life in cancer patients (Hutchinson et al., 2012; 
Pullens et al., 2010).  Continued assessment of patients’ self-reported cognitive 
symptoms is warranted to understand symptom experiences from the patients’ 
perspective (Pullens et al., 2010) and inform patient-centered treatment approaches.  
1.3   Cognitive Symptoms in Metastatic Breast Cancer 
Although most research on cognitive symptoms has focused on early-stage breast 
cancer patients, a few studies have documented self-reported cognitive symptoms in 
metastatic breast cancer patients (Aranda et al., 2005; Bender, Ergÿn, Rosenzweig, 
Cohen, & Sereika, 2005; Mayer, 2010; Mayer & Grober, 2006).  One study found that 
cognitive dysfunction was only reported by 8% of 105 metastatic breast cancer patients 
on the 2-item cognitive subscale of the EORTC QLQ-30 (Aranda et al., 2005).  
Conversely, another survey of metastatic breast cancer patients found that 60% of 618 
patients reported cognitive problems on an author-constructed item (Mayer, 2010).  
Differences in findings across studies may reflect differential measurement of cognitive 
symptoms and sample characteristics: the first study consisted of patients from four urban 
hospitals in Australia (61% response rate) (Aranda et al., 2005), whereas the second study 
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was an online survey of patients from 13 countries (unknown response rate) (Mayer, 
2010; Mayer & Grober, 2006).  Given limitations of the research to date, the prevalence 
of cognitive symptoms in metastatic breast cancer patients is unclear.  
Another study found that one cognitive symptom (i.e., loss of concentration) 
tended to cluster with fatigue, increased weakness, and mood problems in metastatic 
breast cancer patients; however, the analysis was limited to symptoms related to 
menopause (Bender et al., 2005).  This symptom cluster has also been found in early-
stage breast cancer patients and patients with other common cancers (Ahles & Saykin, 
2002; Fan, Filipczak, & Chow, 2007; Ono et al., 2015).  To my knowledge, further 
studies have not documented objective or subjective cognitive symptoms or symptom 
clusters in metastatic breast cancer patients.  Standardized assessment of cognitive and 
other symptoms would contribute to our understanding of the symptom experience of this 
population.   
1.4   Symptom Clusters 
Research on symptom clusters in cancer and non-cancer populations is limited by 
a lack of consensus regarding their conceptual or methodological definition (Dong, 
Butow, Costa, Lovell, & Agar, 2014).  A symptom cluster was originally defined by 
Dodd and colleagues (2001) as “three or more concurrent symptoms” that are related in 
some way (Dodd, Miaskowski, & Paul, 2001).  A more recent definition is that two or 
more symptoms form a cluster if they predictably occur together in a stable group and are 
more strongly associated with each other than with symptoms in separate clusters (Aktas, 
Walsh, & Rybicki, 2010; Dong et al., 2014; Fan et al., 2007; Kim, McGuire, Tulman, & 
Barsevick, 2005).  However, a recent systematic review of the symptom cluster literature 
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on patients with advanced cancer found clusters to be generally unstable both 
longitudinally and methodologically (Dong et al., 2014).  It is also challenging to 
replicate clusters across studies due to a lack of consensus regarding appropriate 
assessment tools, symptom domains, and statistical methodologies (Aktas et al., 2010; 
Dong et al., 2014).  For example, a systematic review found that several studies of 
advanced cancer patients used author-developed symptom checklists with unknown 
psychometric properties, and other studies with this population did not comprehensively 
assess common symptoms (Dong et al., 2014).  Additionally, studies using different 
approaches to statistically derive symptom clusters within the same data set found poor 
stability of clusters between statistical methods (Dong et al., 2014).  However, clusters 
derived with principal component analysis (PCA) and hierarchical cluster analysis (HCA) 
were more strongly correlated than clusters derived with exploratory factor analysis 
(EFA) (Chen et al., 2013; Chen et al., 2012; Dong et al., 2014; Khan et al., 2013).  
Despite methodological and conceptual challenges, symptom clusters are 
especially important to examine in cancer patients for several reasons.  First, when 
multiple symptoms occur together in cancer patients, they often have a compounding 
effect which may impair functional status and decrease quality of life (Cleeland, 2007; 
Cleeland et al., 2003; Dodd, Cho, Cooper, & Miaskowski, 2010; Dodd et al., 2001; 
Kurzrock, 2001; Valentine & Meyers, 2001).  Second, on average, cancer patients 
concurrently experience 11-13 symptoms (Chang, Hwang, Feuerman, & Kasimis, 2000; 
Fan et al., 2007; Portenoy, Thaler, Kornblith, Lepore, Friedlander-Klar, Coyle, et al., 
1994); thus, assessing and treating one symptom at a time is unlikely to have a large 
impact on patients’ distress or quality of life (Miaskowski et al., 2004).   
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Furthermore, identifying symptom clusters informs research and treatment by 
pointing to common mechanisms—both biological and psychological—that may underlie 
various symptoms (Kim, Barsevick, Fang, & Miaskowski, 2012; Miaskowski et al., 
2004).  For example, in cancer patients with various disease sites, pain has been shown to 
cluster with cognitive problems (Fan et al., 2007).  Although this relationship may be 
explained by analgesic medication use, an alternative explanation is that pain demands 
attention, resulting in cognitive deficits when limited attentional resources are focused on 
pain (Eccleston & Crombez, 1999; Grisart & Van der Linden, 2001; Moriarty, McGuire, 
& Finn, 2011).   
Recently, researchers have suggested that cognitive symptoms, pain, fatigue, 
sleep problems, anxiety, and depressive symptoms form a psychoneurological symptom 
cluster with several interacting psychological and biological mechanisms  (Kim et al., 
2012; Starkweather et al., 2013; Wood & Weymann, 2013).  Inflammation is an example 
of a possible biological mechanism underlying the psychoneurological symptom cluster 
(Dong et al., 2014).  Elevated proinflammatory cytokines have been associated with 
greater overall symptom severity in lung cancer patients (Wang et al., 2010) and fatigue 
and cognitive dysfunction in breast cancer patients prior to chemotherapy (Patel et al., 
2015).  Whether inflammation is a cause or an outcome of symptom burden is currently 
unclear, but it appears to be one of many interactive factors influencing symptom 
outcomes (Dong et al., 2014; Kim et al., 2012).  Another common biological mechanism 
that may interact with factors such as inflammation is HPA axis dysregulation (Kim et 
al., 2012).  Animal models suggest that some chemotherapy treatments lead to HPA axis 
dysregulation (Seigers & Fardell, 2011), and stress associated with having cancer may 
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also be associated with this outcome (Kim et al., 2012).  Even after completing treatment, 
breast cancer survivors with chronic fatigue have shown dysregulation of HPA axis 
responsiveness with significantly blunted cortisol response to laboratory stressors 
(Bower, Ganz, & Aziz, 2005).  HPA axis dysregulation has also been found to be 
significantly associated with more sleep disturbance, pain, and depressive symptoms 
among metastatic breast cancer patients (Koopman et al., 2002).  Exploring symptoms 
clusters in metastatic breast cancer patients may inform future research regarding 
common mechanisms of these symptoms such as stress, inflammation, and HPA axis 
dysregulation.  
1.5   Patient Perceptions of Symptom Importance 
Research on symptoms in cancer patients has largely focused on symptom 
severity, frequency, and distress.  Assessing patients’ perceptions of symptom 
importance—how important it is for them to see improvement in a symptom after it is 
treated—would also inform patient-centered treatment approaches.  The goals of patient-
centered treatment are to enhance communication and collaboration between patients and 
clinicians and respect patients’ autonomy (Epstein, Fiscella, Lesser, & Stange, 2010).  
Some evidence suggests that patient-centered treatment improves quality of care, health 
outcomes, and patient satisfaction while reducing financial costs of health care (Epstein 
et al., 2010; Epstein et al., 2005; Fiscella et al., 2004; Little et al., 2001; Mallinger, 
Griggs, & Shields, 2005; Mead & Bower, 2002; Rao, Anderson, Inui, & Frankel, 2007; 
Safran et al., 2006; M. Stewart et al., 2000).  However, a patient-centered approach has 
not been adopted in symptom research with cancer patients; studies have not examined 
patients’ perceptions of the importance of reducing specific symptoms.  
23 
 
 
Perceptions of symptom importance have been examined in research on patients 
with chronic pain conditions.  This research found subgroups of patients who had 
differential perceptions of the importance of improving specific symptoms; some patients 
focused on pain as the most important symptom, whereas others equally valued 
improvement in various symptoms (M. E. Robinson et al., 2005; Yi, Kim, Ha, & Lim, 
2014; Zeppieri et al., 2012).  Evidence suggests that patients with chronic pain who rate 
all symptoms as highly important have increased depressive and anxiety symptoms (Yi et 
al., 2014; Zeppieri et al., 2012).  One study of patients with Parkinson’s disease found 
that they either rated all or none of their symptoms as highly important (Nisenzon et al., 
2011).  Although disease and treatment factors were unrelated to symptom importance 
ratings, low importance ratings were associated with more formal education (Nisenzon et 
al., 2011).  
Treating symptoms such as pain, fatigue, and sleep disturbance may be a greater 
priority for advanced cancer patients than maintaining their cognitive functioning.  For 
example, treating pain with narcotics often results in temporary cognitive impairment 
(Bruera, Macmillan, Hanson, & MacDonald, 1989), and some advanced cancer patients 
may consider pain treatment to be a higher priority than maintaining optimal cognitive 
function.  Yet other patients, especially those with cognitively demanding jobs, may find 
cognitive deficits to be more distressing than other symptoms.  Many metastatic breast 
cancer patients are living for years with this disease and have high levels of functioning 
(Mayer, 2010; Reed et al., 2012).  Despite this population’s increased longevity and 
functional capacity, their cognitive symptoms have received scarce research attention.  
Understanding cognitive symptoms in the context of metastatic breast cancer patients’ 
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symptom treatment priorities informs patient-centered care for this highly burdened and 
prevalent, yet understudied population.   
1.6   The Present Study 
To address gaps in our understanding of metastatic breast cancer patients’ 
cognitive symptoms, the present study has two specific aims: 
Aim 1: Examine the extent to which cognitive complaints cluster with other 
common symptoms (i.e., fatigue, sleep disturbance, depressive symptoms, anxiety, pain, 
hot flashes, lymphedema, neuropathy, and nausea) in metastatic breast cancer patients. 
Hypothesis 1: Cognitive complaints will cluster with fatigue, sleep disturbance, 
depressive symptoms, anxiety, and pain in metastatic breast cancer patients. 
This hypothesis is illustrated in Figure 3 and is based on limited evidence from 
two studies suggesting that fatigue, sleep disturbance, and mood disturbance are 
associated with cognitive complaints in metastatic breast cancer patients (Aranda et al., 
2005; Bender et al., 2005).  One of these studies did not perform a cluster analysis on 
reported symptoms (Aranda et al., 2005).  In the study that included a cluster analysis of 
symptoms, only single-item measures of menopausal symptoms were analyzed (Bender 
et al., 2005).  In the current study, multi-item symptom assessments developed by the 
NIH and validated in cancer populations were used in order to provide a more reliable 
estimate of cognitive and other symptoms in metastatic breast cancer patients. 
This hypothesis is also based on research suggesting that pain tends to cluster 
with cognitive problems in other cancer populations (Fan et al., 2007).  It is estimated 
that 70-90% of patients with advanced cancer have chronic pain (Irvin, Muss, & Mayer, 
2011; Portenoy & Lesage, 1999).  Although the prevalence of chronic pain in metastatic 
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breast cancer patients is unknown, it is estimated that 44-64% of breast cancer patients at 
any stage (excluding survivors with no evidence of disease) have chronic pain (Van den 
Beuken-van Everdingen et al., 2007).  Thus, it is important to examine whether pain 
tends to cluster with cognitive complaints in metastatic breast cancer patients.   
Finally, this hypothesis is based on theory and empirical research suggesting that 
a psychoneurological symptom cluster may have common biological and psychological 
mechanisms (Kim et al., 2012; Miaskowski et al., 2004).  Elevated proinflammatory 
cytokines may be one biological mechanism underlying symptom clusters, as they have 
been associated with greater overall symptom severity in lung cancer patients (Dong et 
al., 2014; Wang et al., 2010) and fatigue and cognitive dysfunction in breast cancer 
patients prior to chemotherapy (Patel et al., 2015).  HPA axis dysregulation is another 
possible common mechanism underlying symptoms such as cognitive symptoms, sleep 
problems, fatigue, pain, anxiety, and depressive symptoms (Bower et al., 2005; Kim et 
al., 2012; Koopman et al., 2002; Seigers & Fardell, 2011). 
Exploratory Aim: To compare metastatic breast cancer patient ratings of symptom 
importance for cognitive symptoms to those of other symptoms (i.e., pain, fatigue, sleep 
disturbance, depression, anxiety, nausea, lymphedema, hot flashes, and neuropathy).  
This aim is exploratory due to the absence of prior research and theorizing on 
cancer patient ratings of symptom importance.  
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CHAPTER 2. METHOD 
This study examines a portion of the data from a Walther-funded study on 
metastatic breast cancer patients’ perceptions of symptom importance and interference.  
The Indiana University Institutional Review Board and IU Simon Cancer Center 
Scientific Review Committee approved all study procedures.  This study complies with 
the Health Insurance Portability and Accountability Act (HIPAA). 
2.1   Participants 
Eighty metastatic breast cancer patients were recruited from the IU Simon Cancer 
Center to participate in a telephone survey.  Eligible participants met the following 
inclusion criteria: female, diagnosis of stage IV breast cancer, at least 18 years old, able 
to speak and read English, and no evidence of cognitive impairment that may limit their 
capacity to give informed consent or participate in the study.  This degree of cognitive 
impairment was based on investigator judgment or exceeding a clinical cutpoint (i.e., 3 or 
more errors) on a validated cognitive screening measure (Callahan, Unverzagt, Hui, 
Perkins, & Hendrie, 2002).  
2.2   Procedure 
IU Simon Cancer Center medical records were screened to identify patients with 
stage IV breast cancer, and their treating oncologists were contacted to verify eligibility 
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for the current study.  Eligible patients were then mailed an introductory letter signed by 
the PI and the patient’s oncologist along with consent and HIPAA authorization forms.  
The letter included an option to call or email the research assistant to decline further 
contact.  Within approximately 1 to 2 weeks after the mailing, the research assistant 
called patients who had not opted-out to describe the study, answer any questions, 
administer a brief cognitive screening assessment (Callahan et al., 2002), and obtain 
verbal informed consent.  Patients who declined study participation were asked to 
provide their reason for study refusal as well as age and race to assess for possible 
selection biases.  If the patient verbally consented to participate, a 45-minute telephone 
assessment was scheduled.  The assessment was administered by a trained research 
assistant and included questions regarding demographic information, medical history, and 
symptom severity and importance.  A subsample of 25 participants with one or more 
symptoms of at least moderate severity (i.e., sleep problems, pain, anxiety, sadness, or 
fatigue) were invited to participate in a separate qualitative phone interview, but the 
qualitative data were not analyzed in the present study.  Participants received a $40 
Target gift card for the first assessment, and those who participated in the qualitative 
interview received an additional $50 Target gift card, for a possible total of $90 in gift 
cards.   
2.3   Measures 
 The following sections describe measures analyzed in the current study and time 
points for data collection. 
Brief screening measure for probable dementia. The cognitive screener was a 
6-item assessment of global cognitive functioning.  The 6 items were taken from the 
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Mini-Mental State Examination, a commonly used and validated measure (Cockrell & 
Folstein, 2002).  Three items assess orientation to time, which increase the measure’s 
specificity for assessing probable dementia (Callahan et al., 2002).  The other 3 items 
assess short-term word recall, which increase the measure’s sensitivity because deficits in 
short-term word recall are highly indicative of cognitive impairment (Callahan et al., 
2002).  Patients were ineligible if they missed 3 or more items on this measure, as this 
suggested that they lacked the capacity to provide consent and accurate responses to 
study questions.  A cutoff score of 3 or more errors has been shown to have 88.7% 
sensitivity and 88.0% specificity for a diagnosis of dementia (Callahan et al., 2002).  
Although including this screener limited the range of cognitive abilities of study 
participants, mild to moderate cognitive symptoms that were not confounded with a 
diagnosis of dementia were the focus of this study.  
Demographics.  Participants were asked to report their marital status, race, 
ethnicity, education, income, and employment status.  Age was assessed via medical 
record review.  
Medical information.  The following information was collected from the medical 
record after informed consent: diagnosis date and cancer treatment history (i.e. surgeries, 
chemotherapy, radiation, hormone therapy, targeted therapy, bisphosphonates, and other 
treatment). 
Medical comorbidities.  A self-report measure of 9 medical conditions was used 
to assess the presence of comorbid conditions that were diagnosed or treated within the 
last 3 years (Kroenke et al., 2009).  This measure has been used in NIH-funded research 
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with cancer patients (Kroenke et al., 2009).  Reliability and validity of this measure have 
not been established, as this is a checklist rather than a scale (Kroenke et al., 2009).  
Cognitive complaints.  General cognitive concerns were assessed with a 4-item 
Patient Reported Outcomes Information System (PROMIS) measure (Cella et al., 2010).  
Patients were asked to rate the frequency of their cognitive complaints (e.g., “My 
thinking has been slow…”) over the past 7 days on a scale from 1 (never) to 5 (very 
often). 
The development of PROMIS measures was funded by the NIH to create a 
standardized way to reliably assess patient-reported health outcomes (Cella et al., 2010; 
Cella et al., 2007).  Standardized T scores with a mean of 50 and a standard deviation of 
10 can be used to compare scores to population norms.  Cancer patients were involved in 
focus groups to develop items for PROMIS measures (Garcia et al., 2007), and several 
publications have demonstrated the PROMIS measures’ reliability and validity in cancer 
populations with early to late-stage disease (Baum, Basen-Engquist, Swartz, Parker, & 
Carmack, 2014; Stachler, Schultz, Nerenz, & Yaremchuk, 2014; Wagner et al., 2015; 
Yost, Eton, Garcia, & Cella, 2011).  Initial development of PROMIS short-forms showed 
excellent internal consistency reliability of each of the symptom measures and strong 
correlations between short forms and item banks (r > .96) (Cella et al., 2010).  PROMIS 
items also have good convergent validity, as evidenced by moderate to strong 
correlations between these items and similar legacy measures (r ranges from .69 to .96) 
(Cella et al., 2010).  
Other physical and psychological symptoms.  Nine additional physical and 
psychological symptoms were selected for assessment in the current study due to their 
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high prevalence in metastatic breast cancer patients (Aranda et al., 2005; Bender et al., 
2005; Carpenter et al., 1998; Given et al., 2008; Grabsch et al., 2006; Holmes et al., 1991; 
Ozaslan & Kuru, 2004; Palesh et al., 2007).  PROMIS measures (Cella et al., 2010) were 
used to assess some of these symptoms.  Specifically, 4-item PROMIS measures were 
used to assess four of these symptoms during the past week, including depressive 
symptoms and anxiety on a scale from 1 (never) to 5 (always), fatigue on a scale from 1 
(not at all) to 5 (very much), and sleep disturbance with the first item (i.e., “My sleep 
quality was…”) rated on a scale from 1 (very poor) to 5 (very good) and subsequent items 
rated on a scale from 1 (not at all) to 5 (very much).  A 3-item PROMIS measure was 
used to assess pain intensity over the past week on a scale from 1 (no pain) to 5 (very 
severe).  
No PROMIS measures have been developed to assess nausea, hot flashes, 
lymphedema, or neuropathy.  Thus, these symptoms were assessed with other validated 
measures.  Items from the Memorial Symptom Assessment Scale (MSAS) (Portenoy, 
Thaler, Kornblith, Lepore, Friedlander-Klar, Kiyasu, et al., 1994) were used to measure 
nausea, peripheral neuropathy, and lymphedema.  Patients were asked to indicate whether 
they had experienced the symptom in the past week, and those who answered yes were 
asked to rate the frequency of the symptom over the past week on a scale from 1 (rarely) 
to 4 (almost constantly).  In addition, patients reported usual symptom severity over the 
past week on a scale from 1 (slight) to 4 (very severe) and the extent to which the 
symptom was distressing on a scale from 0 (not at all) to 4 (very much).  Lymphedema 
symptom assessment does not include a question about frequency because it is not 
relevant for this symptom (Portenoy, Thaler, Kornblith, Lepore, Friedlander-Klar, 
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Kiyasu, et al., 1994).  In research with cancer patients, the MSAS had moderate to high 
internal consistency for physical symptom assessment (Cronbach’s α ranges from 0.58 to 
0.88) and showed evidence of convergent and discriminant validity (Portenoy, Thaler, 
Kornblith, Lepore, Friedlander-Klar, Kiyasu, et al., 1994).  For example, it was highly 
correlated with other measures of clinical status and quality of life (e.g., r ranges from -
0.52 to -0.75 for MSAS physical symptoms and the Functional Living Index-Cancer) 
(Portenoy, Thaler, Kornblith, Lepore, Friedlander-Klar, Kiyasu, et al., 1994).  
The MSAS does not include an assessment of hot flashes; thus, this symptom was 
assessed with a brief measure developed to assess hot flashes in breast cancer patients 
treated with hormone therapy (Carpenter et al., 1998).  Similar to the MSAS, patients 
were first asked to indicate whether they had experienced hot flashes, and those who 
answered yes were asked to rate their severity on a scale from 0 (not at all) to 4 
(extremely) and the extent to which they were bothersome on a scale from 0 (not at all 
bothered) to 10 (extremely bothered).  Unlike the MSAS, patients were asked if they have 
experienced hot flashes over the past two weeks rather than one week.  This time period 
is similar to that of prior research (Brambilla, Mckinlay, & Johannes, 1994; Carpenter et 
al., 1998; Hemminki, Topo, & Kangas, 1995).  Hot flashes tend to be periodic 
(Kronenberg, 1990); thus, limiting the assessment time period to one week may 
significantly decrease the sensitivity of the measure.  
Perceptions of symptom importance.  Patient perceptions of symptom 
importance were assessed with the Patient Centered Outcomes Questionnaire (PCOQ) 
(Robinson et al., 2005), which was modified to include the symptoms described above.  
The modified PCOQ consists of four sections, whereas the original PCOQ had five 
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sections.  We omitted the section on desired level of symptom severity because ideal 
outcomes were likely to be “none” for the majority of patients.  This section was omitted 
in another study using a modified version of the PCOQ with a different medical 
population (Nisenzon et al., 2011).  In the first section of the modified PCOQ in the 
current study, patients were asked to report their usual level of symptom severity over the 
past week on a scale of 0 (none) to 10 (worst imaginable) for each of the 10 symptoms 
(i.e. pain, fatigue, anxiety, sadness, numbness/tingling in hands/feet, swelling of arms or 
legs, nausea, hot flashes, sleep problems, attention/thinking/memory problems).  In the 
second section, patients were asked to report for each symptom the level of symptom 
severity that they would consider a treatment success on a scale of 0 (none) to 10 (worst 
imaginable).  In the third section, patients were asked to report for each symptom their 
expected symptom severity following treatment of the symptom on a scale of 0 (none) to 
10 (worst imaginable).  In the fourth and final section, patients were asked to rate the 
importance of experiencing improvement in each of their symptoms on a scale of 0 (not 
at all important) to 10 (most important).  Because an aim of this study was to compare 
metastatic breast cancer patient ratings of symptom importance for cognitive symptoms 
to those of other symptoms, analysis of this measure focused exclusively on the fourth 
section. 
The PCOQ was originally developed for patients with chronic pain, and the 
original version showed adequate test-retest reliability over a 48 hour period (values 
ranging from 0.84 to 0.90) and good convergent validity with other standardized 
measures of pain, emotional distress, and disability (r values ranging from 0.52 to 0.75) 
(Brown et al., 2008). 
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2.4   Data Analysis 
 Data were analyzed with SPSS (IBM SPSS Statistics for Windows, Version 23.0; 
Armonk, NY, USA) and R (R Foundation for Statistical Computing, Version 3.2.3; 
Vienna, Austria) statistical software.  Minimal missing data were expected; thus, listwise 
deletion would have been employed (i.e., all cases with missing data would be excluded 
from analyses).  However, none of the data were missing.  To examine symptoms on the 
same metric, scores for all measures of symptom severity (i.e., PROMIS measures, 
MSAS subscales, and the hot flashes assessment) were converted to z scores.  Data were 
then examined for possible outliers, and Winsorization transformation was employed in 
order to reduce the influence of any extreme values by modifying scores to equate to z-
scores with an absolute value of 3.0 (i.e., to 3 standard deviations of the mean) (Tukey, 
1962).  The assumption of normality was examined by computing skewness and kurtosis 
indices, which should be less than the absolute values of 3.0 and 8.0, respectively (Kline, 
2011).  If the assumption of normality was violated, the appropriate variable 
transformation (i.e., log or square root) would have been employed based on the 
characteristics of the violation, and sensitivity analyses would have been performed to 
determine differential effects of data transformations.  Frequencies, means, and standard 
deviations were computed to characterize patient demographics, medical information, 
and symptom levels (i.e. cognitive complaints, hot flashes, nausea, lymphedema, 
neuropathy, depression, anxiety, sleep disturbance, fatigue, and pain) as well as ratings of 
symptom importance for each of the 10 symptoms. Chronbach’s alphas were computed 
for multi-item assessments. 
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To test the hypothesis that cognitive complaints would cluster with fatigue, sleep 
disturbance, depressive symptoms, and anxiety, an agglomerative hierarchical cluster 
analysis was performed on the z scores for the 10 symptoms.  This provided subgroups of 
co-occurring symptoms, allowing me to determine which symptoms tended to cluster 
with cognitive complaints.  Squared Euclidian distances were used in the proximities 
matrix, and weighted average linkage was used as the clustering method (Everitt, Landau, 
& Leese, 2001; McQuitty, 1966).  This cluster analysis method is frequently used in 
symptom cluster research with cancer patients (Bender et al., 2005; Dodd et al., 2010; 
Glaus et al., 2006; Miaskowski et al., 2006; Ridner, 2005).  There is no reason to expect 
similar subgroup sizes; thus, this clustering method is preferable to Ward’s method—
another commonly used cluster analysis method—which forms spherical clusters, forcing 
the clusters to have similar sizes (Everitt et al., 2001).  Because cluster analysis is an 
exploratory method of examining multivariate relationships, no formal power analysis 
based on sample size is feasible (Everitt et al., 2001; Kozachik, 2006).  
To test the exploratory aim, a within-factors ANOVA was performed to compare 
patient ratings of the importance of symptom improvement for cognitive symptoms to 
those of nine other symptoms (i.e., pain, fatigue, sleep disturbance, depression, anxiety, 
nausea, lymphedema, hot flashes, and neuropathy).  Planned simple contrasts were then 
performed to compare importance ratings between all symptom pairs while preventing 
alpha inflation.  We estimated the statistical power to detect a difference between 
importance ratings with the G*Power statistical power analysis program (Faul, Erdfelder, 
Lang, & Buchner, 2007).  A sensitivity power analysis for a within-factors ANOVA was 
performed.  With a sample size of 80 and an alpha of 0.05, we had 80% power to detect a 
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small effect size (f = 0.10).  Prior research using the PCOQ has not compared the 
importance ratings for different symptoms; thus, we do not have an empirical basis for 
estimating the effect size.  
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CHAPTER 3. RESULTS 
3.1   Preliminary Analyses 
 Descriptive statistics.  Participant characteristics are shown in Table 2.  On 
average, participants were 55.5 years of age (SD = 11.26), had 15.03 years of education 
(SD = 2.42), and were 3.93 years from their stage IV breast cancer diagnosis (SD = 3.64).  
The majority of participants were Caucasian (91.3%), married or partnered (66.3%), and 
earning an annual household income of $51,000 or higher (55.1%).  Regarding cancer 
treatment history, the majority of participants had received chemotherapy (86.3%), 
hormonal therapy (85.0%), radiation (65.0%), and a mastectomy (66.3%).  The most 
prevalent medical comorbidities reported by participants were hypertension (32.5%) and 
arthritis (25.0%).  There was an 87% acceptance rate for study participation (83 patients 
consented to participate out of 95 contacted by phone), and a 96% completion rate for 
those who consented to participate (see Figure 4). 
Following Winsorization transformation of four outliers in the main study 
variables to 3 standard deviations of the mean, their means, standard deviations, and 
ranges were examined (see Table 4).  All values were within the ranges expected for the 
measures.  Cronbach’s alphas for symptom assessments also were examined (see Table 
4).  Internal consistency reliability was good for PROMIS-measured symptoms (αs = 
0.83 to 0.95) and MSAS-measured symptoms (αs = 0.89 to 0.95), and adequate for the
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hot flashes assessment (α = 0.75).  The limited information regarding metastatic breast 
cancer patients’ symptom experiences precludes comparisons of the current mean 
symptom levels of nausea, neuropathy, swelling, and hot flashes to prior literature.  Total 
scores for symptoms measured with PROMIS instruments (i.e., pain, fatigue, sleep 
problems, cognitive problems, anxiety, and depressive symptoms) were uploaded to the 
scoring service on the PROMIS assessment center website (www.assessmentcenter.net), 
and T-scores were derived for each symptom.  The scoring service returned spreadsheets 
for each symptom with each participant’s calibrated T-scores.  These T-scores were 
calibrated to the cancer sample when available (i.e., anxiety, cognitive concerns, 
depressive symptoms, and fatigue).  For measures of pain and sleep disturbance, data 
from a cancer sample were unavailable; thus, T-scores were calibrated to the wave 1 
general population sample.   
The cancer calibration sample consisted of 1,754 participants that completed 
PROMIS measures on a web-based polling platform and self-reported a cancer diagnosis 
(Cella et al., 2010).  The cancer stage of participants in the cancer population sample has 
not been reported.  The wave 1 general population sample consisted of 21,133 
participants (including clinical samples such as those who reported cancer) who were 
52% female with a mean age of 50 years, and this sample has been shown to be 
representative of the general U.S. population (Cella et al., 2010; Liu et al., 2010).  The 
means and standard deviations for the current sample’s calibrated T-scores for PROMIS 
symptom measures are reported in Table 5.  Mean calibrated T-scores for all PROMIS 
symptom measures were within one standard deviation of 50 (i.e., the average for the 
respective calibration sample).  Additionally, unpublished results from a study of 634 
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metastatic breast cancer patients showed average T-scores for PROMIS measures of pain, 
fatigue, sleep disturbance, anxiety, depressive symptoms, and cognitive function within 1 
standard deviation of those reported in the current sample (R. Jensen, personal 
communication, April 8, 2016).  Regarding symptom importance ratings, there are no 
prior reports in cancer patients to serve as a comparison.  
Tests of assumptions of cluster analysis and ANOVA.  None of the data were 
missing.  Data were screened for outliers (i.e., z-scores +/- 3), and Winsorization 
transformation was employed on four outliers to reduce the influence of these extreme 
values while still representing the sample distribution (Tukey, 1962) (see Table 3).  After 
Winsorization, the normality of symptom ratings and symptom importance ratings was 
examined with skewness and kurtosis indices (see Table 4).  Skewness and kurtosis 
indices were all less than the absolute values of 3.0 and 8.0 respectively; therefore, the 
data were normally distributed (Kline, 2011).  The assumption of sphericity for a 
repeated-measures ANOVA on ratings of the importance of the ten symptoms was 
examined with Mauchly’s test of sphericity.  Mauchly’s test was significant (W = 0.06, 
χ2(44, N = 80) = 213.75, p < 0.05); therefore, the assumption of sphericity for a repeated-
measures ANOVA was violated.  In other words, the variances of the differences 
between symptom importance ratings were not equal.  This violation is common when 
there are more than three repeated measures, and patients rated the importance of ten 
symptoms.  When the assumption of sphericity is violated, the F-ratio should be 
interpreted with caution, and the appropriate correction to the degrees of freedom should 
be employed (Warner, 2013).  The Greenhouse-Geisser correction to degrees of freedom 
was appropriate because ε < 0.75 (Girden, 1992). 
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3.2   Analyses for Aim 1 
To examine symptoms that co-occurred with cognitive complaints in metastatic 
breast cancer patients, a hierarchical agglomerative cluster analysis was performed with 
squared Euclidean distance and weighted average linkage.  Results of this cluster analysis 
are shown in Figures 5 and 6.  The number of clusters may be determined by examining 
the dendrogram (see Figure 5) and determining the “best cut” at the height of the 
dendrogram below which the changes in fusion levels are smaller relative to the changes 
above the cut (Everitt et al., 2001).  The best cut for the current cluster analysis is 
approximately at a height of 115 on the dendrogram (see Figure 6).  Findings partially 
supported my hypothesis that cognitive symptoms would cluster with fatigue, sleep 
problems, anxiety, depressive symptoms, and pain.  Specifically, cognitive symptoms 
clustered with all of these symptoms except for pain.  Another cluster consisted of pain, 
neuropathy, and nausea.  Hot flashes and swelling failed to cluster with other symptoms.   
There were three outlying symptom scores that were Winsorized prior to the 
cluster analysis.  A sensitivity analysis was performed such that another hierarchical 
agglomerative cluster analysis with squared Euclidean distance and weighted average 
linkage was conducted with the non-Winsorized values.  Results of this cluster analysis 
are shown in Figures 7 and 8.  Without reducing the influence of extreme values for 
swelling, anxiety, and depressive symptoms, the cluster of symptoms co-occurring with 
cognitive complaints did not change.  However, swelling clustered with pain, neuropathy, 
and nausea.  Hot flashes again failed to cluster with other symptoms. 
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3.3   Analyses for Aim 2 
To assess differences between importance ratings for the ten examined symptoms, 
a repeated-measures ANOVA was performed.  Because the assumption of sphericity was 
violated, the Greenhouse-Geisser correction to the degrees of freedom was employed.  
Results of the repeated-measures ANOVA are shown in Table 6.  Symptom importance 
ratings were significantly different among the ten symptoms, F(5.8, 457.97) = 13.77, p < 
0.001; the corresponding effect size for this difference was an η2 of 0.15.  It is noteworthy 
that after the Greenhouse-Geisser correction was applied to the degrees of freedom for F, 
the obtained F remained statistically significant.  
Planned simple contrasts were conducted to compare mean symptom importance 
for cognitive symptoms (i.e., thinking problems) to each of the nine other symptoms (see 
Table 7 and Figure 9).  The importance of cognitive symptoms was significantly greater 
than anxiety (MD = 1.11, p < 0.05), depressive symptoms (i.e., sadness) (MD = 1.33, p < 
0.05), neuropathy (MD = 1.98, p < 0.05), swelling (MD = 2.76, p < 0.05), nausea (MD = 
1.44, p < 0.05), and hot flashes (MD = 2.28, p < 0.05).  There were no significant 
differences in importance for cognitive symptoms, pain, fatigue, and sleep problems. 
There was one outlying symptom importance value that was Winsorized prior to 
the repeated-measures ANOVA and planned contrasts.  A sensitivity analysis was 
performed with the non-Winsorized value, and the results did not change. 
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CHAPTER 4. DISCUSSION 
 Broadly, the purpose of this study was to characterize metastatic breast cancer 
patients’ symptom experiences and treatment priorities with respect to cognitive and 
other symptoms.  Because recent advances in treatment have resulted in increased 
longevity for metastatic breast cancer patients, these patients may live for years with 
cognitive problems affecting their quality of life and functional capacity.  However, little 
research has examined cognitive symptoms in metastatic breast cancer patients and their 
co-occurrence with other common symptoms.  Additionally, symptom importance, or the 
degree to which symptoms are viewed as treatment priorities, has not been examined in 
any cancer population.  Understanding metastatic breast cancer patients’ symptom 
experiences and treatment priorities is a crucial step in developing patient-centered 
approaches to symptom management.  Such approaches may improve the quality and cost 
of care as well as patients’ adherence to treatment recommendations. 
4.1   Symptom Cluster Findings 
 The first aim of the study was to examine the extent to which cognitive 
complaints cluster with other common symptoms (i.e., fatigue, sleep disturbance, 
depressive symptoms, anxiety, pain, hot flashes, lymphedema, neuropathy, and nausea) in 
metastatic breast cancer patients.  I hypothesized that cognitive complaints would cluster 
with fatigue, sleep disturbance, depressive symptoms, anxiety, and pain.  This hypothesis 
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was informed by limited evidence from prior studies of metastatic breast cancer patients’ 
symptom experiences (Aranda et al., 2005; Bender et al., 2005), the finding that pain 
tends to cluster with cognitive complaints in people with other cancer types (Fan et al., 
2007), and theoretical and empirical support for common psychological and biological 
mechanisms underlying a psychoneurological symptom cluster (Bower et al., 2005; Dong 
et al., 2014; Kim et al., 2012; Koopman et al., 2002; Miaskowski et al., 2004; Patel et al., 
2015; Seigers & Fardell, 2011; Wang et al., 2010).  Findings from the current study 
partially supported my hypothesis.  Cognitive complaints were found to cluster with 
fatigue, sleep disturbance, depressive symptoms, and anxiety.  A separate symptom 
cluster consisted of pain, neuropathy, and nausea.  Hot flashes and swelling failed to 
cluster. 
 The symptom clusters found in the current study are partially consistent with 
findings from the symptom cluster literature with various cancer populations (Bender et 
al., 2005; Bruera, 2013; Chen et al., 2013; Fan et al., 2007; Jiménez et al., 2011).  To my 
knowledge, only one prior study has examined cognitive symptoms and symptom clusters 
in metastatic breast cancer patients, and findings indicated that loss of concentration 
clustered with anxiety, depressive symptoms, fatigue, and decreased physical strength 
(Bender et al., 2005).  Sleep disturbance was also assessed in this prior study, but failed 
to cluster.  When examining the symptom cluster literature on advanced cancer patients, 
anxiety and depressive symptoms appear to be the most consistently obtained symptom 
cluster (Bender et al., 2005; Bruera, 2013; Cheung, Le, & Zimmermann, 2009; Edward 
Chow, Fan, Hadi, & Filipczak, 2007; E Chow et al., 2008; Dong et al., 2014; Fan et al., 
2007; Hird et al., 2010; Jiménez et al., 2011; Kirkova, Aktas, Walsh, Rybicki, & Davis, 
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2010; Walsh & Rybicki, 2006; Yennurajalingam et al., 2013).  Occasionally, anxiety and 
depressive symptoms have also been found to cluster with other symptoms such as sleep 
problems (Jiménez et al., 2011; Walsh & Rybicki, 2006) and fatigue (Chen et al., 2013) 
in advanced cancer patients.  Regarding cognitive symptoms, memory difficulties have 
been found to cluster with pain, fatigue, sleep problems, sadness, and neuropathy in 
several studies examining the validity of the M.D. Anderson Symptom Inventory among 
medically and ethnically diverse cancer patients (Cleeland et al., 2000; Fan et al., 2007; 
Okuyama et al., 2003; Wang et al., 2006; Wang et al., 2004).  In addition, a study of non-
metastatic breast cancer patients receiving chemotherapy or radiation found a 
psychoneurological symptom cluster consisting of cognitive symptoms, depressed mood, 
fatigue, insomnia, and pain (Kim, Barsevick, Tulman, & McDermott, 2008).   
  Recently, biological and psychological mechanisms underlying the 
psychoneurological symptom cluster in non-metastatic breast cancer patients have been 
explored.  These mechanisms include oxidative stress, telomere shortening, DNA 
damage, proinflammatory cytokines, HPA axis dysfunction, and perceived stress (Kim et 
al., 2012; Starkweather et al., 2013; Wood & Weymann, 2013).  Oxidative stress and 
telomere shortening—two factors involved in DNA damage—have been shown to be 
associated with cancer and chemotherapy treatment (Calado & Young, 2012), memory 
impairments and decreased grey matter density in breast cancer survivors (Conroy et al., 
2013), muscle weakness and fatigue in patients with various cancer types (Gilliam & St. 
Clair, 2011), and major depressive disorder in non-cancer populations (Wolkowitz et al., 
2011).  Elevated proinflammatory cytokines have been associated with fatigue and 
cognitive symptoms in breast cancer patients (Patel et al., 2015), greater symptom burden 
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in lung cancer patients (Wang et al., 2010), and depressive symptoms in patients with 
various cancer types (Dunn et al., 2013).  HPA axis dysregulation has also been found to 
be significantly associated with chronic fatigue in breast cancer survivors (Bower et al., 
2005), and more sleep disturbance, pain, and depressive symptoms in metastatic breast 
cancer patients (Koopman et al., 2002) .  Chronic perceived stress associated with the 
diagnosis and management of cancer has been correlated with increased proinflammatory 
cytokines, HPA axis dysregulation, fatigue, sleep disturbance, and pain in patients with 
metastatic breast cancer and other cancer types (Bower et al., 2009; Koopman et al., 
2002).  
In the present study, the cluster of symptoms including cognitive complaints (i.e., 
cognitive complaints, fatigue, sleep problems, anxiety, and depressive symptoms) seems 
to be consistent with a psychoneurological symptom cluster.  Pain may not have clustered 
with the other psychoneurological symptoms due to differences in measurement, as pain 
was assessed with a 3-item PROMIS measure and the other symptoms in the 
psychoneurological symptom cluster were assessed with 4-item PROMIS measures.  
Instead, pain clustered with symptoms that were assessed with 3-item MSAS measures.  
However, differences in variance between pain and the symptoms assessed with the 4-
item PROMIS measures were small (i.e., 3-13 for pain, 4-20 for fatigue, sleep problems, 
and cognitive problems, and 4-16 for anxiety and depressive symptoms) and MSAS 
assessments had smaller ranges (i.e., 0-3 for nausea and 0-3.67 for neuropathy).  Also, z 
scores were computed for each of the symptom scores prior to the cluster analysis in 
order to place the symptom scores on the same metric.   
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Alternatively, pain may have clustered with neuropathy instead of the other 
psychoneurological symptoms because participants may have been experiencing 
neuropathic pain.  In non-metastatic breast cancer patients treated with certain 
chemotherapies (i.e., taxanes), the numbness and tingling sensations of neuropathy 
predict later development of neuropathic pain (Reyes-Gibby, Morrow, Buzdar, & Shete, 
2009).  The progression of neuropathy to neuropathic pain increases with multiple lines 
of chemotherapy (Swain & Arezzo, 2008), and some metastatic breast cancer patients in 
our sample may have received multiple lines of chemotherapy.  In addition, nausea may 
have clustered with neuropathy and pain because it is also a common side effect of 
chemotherapies (Hesketh 2008).  However, taxane chemotherapies that are often 
associated with neuropathy are less emetogenic than other types of chemotherapies 
(Ghersi et al., 2015).  Future research may benefit from exploring relationships between 
symptom clusters and types of ongoing chemotherapy treatments as well as other ongoing 
treatments among metastatic breast cancer patients.  In addition, assessing pain types 
(e.g., neuropathic pain) would extend the current findings. 
With the exception of sleep problems, the symptoms that clustered with cognitive 
complaints are consistent with findings from the only other published study to conduct a 
cluster analysis on symptoms in metastatic breast cancer patients (Bender et al., 2005).  
Findings from the symptom cluster literature are often slightly inconsistent; for instance, 
symptom clusters derived with different statistical methodologies—even from the same 
sample—are found to be unstable (Dong et al., 2014).  Because cluster analysis is a data-
driven exploratory statistical approach, current findings of symptoms clusters may be 
specific to this sample and should be replicated in future research.  Differences in 
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measurement can also contribute to differential findings across studies.  Most symptoms 
in the current study were assessed with validated measures, while single-item measures 
of menopausal symptoms were used in the prior study of symptom clusters in metastatic 
breast cancer patients (Bender et al., 2005).   
4.2   Symptom Importance Findings 
Whereas findings from the first aim provide information about co-occurring 
symptoms, findings from the second aim increase our understanding of metastatic breast 
cancer patients’ treatment priorities.  Specifically, the second aim was to compare patient 
ratings of symptom importance for cognitive symptoms to those of other symptoms (i.e., 
pain, fatigue, sleep disturbance, depression, anxiety, nausea, lymphedema, hot flashes, 
and neuropathy).  There was no empirical or theoretical basis for a hypothesis; therefore, 
this aim was exploratory.  Patients were found to rate cognitive symptoms as significantly 
more important than anxiety, depressive symptoms, neuropathy, swelling, nausea, and 
hot flashes.  Importance ratings for cognitive symptoms, pain, fatigue, and sleep 
problems were not significantly different.   
The current study was the first to statistically compare ratings of symptom 
importance for different symptoms in any medical population.  Rather than comparing 
importance ratings, prior research on symptom importance in certain medical populations 
(i.e., patients with chronic pain and Parkinson’s disease) has found subgroups of patients 
based on their ratings of symptom importance (Nisenzon et al., 2011; M. E. Robinson et 
al., 2005).  These subgroups typically consist of patients who rate all symptoms as high, 
moderate, or low in importance.  In patients with chronic pain, researchers have also 
found subgroups of patients who consider pain to be most important (M. E. Robinson et 
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al., 2005).  Thus, significant differences in symptom importance ratings in the current 
study converge with chronic pain research indicating that some symptoms are considered 
more important than others. 
Several factors may explain the current findings regarding ratings of symptom 
importance.  First, metastatic breast cancer patients may have been more comfortable 
giving a higher importance rating to cognitive symptoms than anxiety and depressive 
symptoms because emotional disturbances among cancer patients may be stigmatizing 
(Holland, 2002; Holland, Kelly, & Weinberger, 2010; Knowles, Chew-Graham, 
Adeyemi, Coupe, & Coventry, 2015).  There are several lines of evidence pointing to 
stigma associated with emotional disturbances, including cancer patients’ underuse of 
psychosocial support services (Abbott et al., 2013); one study found that only 14% of a 
heterogeneous sample of cancer patients reported using psychosocial support services 
over a period of 6 months, and this sample was moderately distressed on average 
(McDowell, Occhipinti, Ferguson, & Chambers, 2011).  Additionally, many cancer 
patients endorse barriers to support services use that may be related to stigma, such as 
discomfort with seeking counseling and the belief that counseling may be more upsetting 
than helpful (Eakin & Strycker, 2001).   
Second, some of the current differences in symptom importance ratings mirrored 
differences in symptom severity; specifically, usual levels of cognitive complaints, pain, 
fatigue, and sleep problems appeared to be higher in severity than neuropathy, swelling, 
nausea, and hot flashes.  The mean severity ratings for cognitive complaints, pain, 
fatigue, and sleep problems fell within 40% of the total possible range, while those for 
neuropathy, hot flashes, nausea, and swelling were lower and fell within 15-30% of the 
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total possible range.  However, the clinical significance of this numerical difference is 
unclear.   
Third, high importance ratings for pain, sleep disturbance, and fatigue as well as 
cognitive symptoms may reflect the distressing quality of these symptoms.  Pain, sleep 
disturbance, and fatigue have been found to be highly prevalent and distressing 
symptoms among patients with various advanced cancers (Butt, Wagner, et al., 2008; 
Reilly et al., 2013).  In addition, when cancer patients in two studies ranked symptoms 
according to the importance of monitoring them, fatigue was consistently ranked as most 
important, and pain was among the top 5-6 most important (Butt, Rosenbloom, et al., 
2008; Cella et al., 2011; Reeve et al., 2014).  Sleep disturbance and cognitive problems 
were only examined in one of these studies.  Of 533 advanced cancer patients who ranked 
11 symptoms on the importance of monitoring them, 48% ranked fatigue as most 
important (ranked 1st), 16% ranked insomnia as most important (ranked 5th), 11% ranked 
pain as most important (ranked 6th), and only 3% ranked cognitive problems as most 
important (ranked 11th) (Cella et al., 2011; Reeve et al., 2014).  Further research is 
needed to determine the degree to which cognitive symptoms are considered a clinical 
priority among advanced cancer patients. 
Fourth, the symptoms rated as equally important in this study (i.e., cognitive 
symptoms, pain, fatigue, and sleep problems) may be difficult to distinguish from one 
another at times.  There may be common biological and psychological mechanisms 
involved in these symptoms such as oxidative stress, telomere shortening, DNA damage, 
proinflammatory cytokines, HPA axis dysfunction, and perceived stress (Kim et al., 
2012; Starkweather et al., 2013; Wood & Weymann, 2013).  These symptoms have also 
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been found to exacerbate each other and have a compounding effect on health and 
quality-of-life outcomes in cancer populations (Cleeland, 2007; Dodd et al., 2010; 
Husain, Myers, Selby, Thomson, & Chow, 2011; Miaskowski et al., 2006). 
Although statistically significant differences in importance ratings were obtained 
in the present sample, it is unclear whether these are clinically meaningful differences.  
Mean importance ratings for cognitive symptoms, pain, fatigue, and sleep problems 
ranged from 7.23 to 7.96, whereas mean importance ratings for anxiety and depressive 
symptoms ranged from 6.36 to 6.58 and those for neuropathy, swelling, and hot flashes 
ranged from 4.93 to 5.71.  There is currently no established standard for a clinically 
meaningful difference in symptom importance; therefore, the present findings are 
difficult to interpret.  Future research may determine clinically meaningful differences by 
examining levels of symptom importance that predict patient-centered care outcomes 
such as adherence to treatment recommendations.  Furthermore, mixed-methods designs 
may examine differences between patient’s ratings and rankings of symptom importance 
and elucidate patients’ decision-making processes for determining symptom importance. 
4.3   Synthesis of Findings for Symptom Clusters and Importance 
Overall, findings suggest that assessing symptom clusters and symptom 
importance provides a more comprehensive picture of symptom experiences.  
Interestingly, cognitive symptoms were found to cluster with anxiety, depressive 
symptoms, sleep disturbance, and fatigue, but cognitive symptoms were rated as 
significantly more important than anxiety and depressive symptoms.  Therefore, the co-
occurrence of symptoms in metastatic breast cancer patients does not necessarily indicate 
that these symptoms are perceived as equally important to treat.  It is possible that 
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focusing treatment on physical symptoms is more palatable to some cancer patients 
compared to psychological symptoms because of stigma associated with anxiety and 
depressive symptoms (Holland, 2002; Holland et al., 2010).  Alternatively, physical 
symptoms may be more noticeable than psychological symptoms for patients with less 
insight into their psychological state.  Again, differences in importance ratings across 
symptoms should be cautiously interpreted until further studies explore the degree to 
which these differences are clinically meaningful. 
4.4   Research and Clinical Implications 
The current findings regarding symptom clusters and importance have a number 
of implications for future research and clinical practice.  Theoretically, patient ratings of 
symptom importance inform patient-centered care by providing information about 
patients’ treatment priorities (Zeppieri et al., 2012).  There is some evidence that patient-
centered care improves the quality and cost of care as well as patients’ adherence to 
treatment recommendations, although findings are mixed (Rathert, Wyrwich, & Boren, 
2013; J. H. Robinson, Callister, Berry, & Dearing, 2008).  Increased adherence to 
treatment recommendations in patient-centered care may be due in part to focusing on the 
patients’ priorities.  As an example, motivational interviewing is an effective behavioral 
intervention for improving treatment adherence which has a focus on patients’ priorities.  
A central component of motivational interviewing is assisting patients in generating 
motivation to change based on their own values—what is important to them (Rollnick & 
Miller, 1995).  This approach from motivational interviewing may be applied to future 
symptom management interventions.  Such interventions may assist patients in 
generating motivation to adhere to treatment recommendations by tailoring those 
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recommendations to target symptoms rated as most important.  Furthermore, future 
research may compare adherence between patients assigned to symptom management 
interventions that are tailored or untailored to symptoms rated as highly important.   
Another potential direction for future research is testing treatments targeting one 
or more symptoms that cluster with other symptoms and are rated as highly important.  
Symptoms in a cluster may exacerbate one another (Cleeland, 2007; Dodd et al., 2010; 
Husain et al., 2011; Miaskowski et al., 2006; Starkweather et al., 2013); therefore, 
treatment focused on one symptom rated as highly important may still provide patients 
some relief from the other symptoms in the cluster and enhance adherence.  For example, 
Cognitive Behavioral Therapy for Insomnia (CBT-I) is an evidence-based treatment for 
insomnia (Okajima, Komada, & Inoue, 2011).  If CBT-I can be used to alleviate sleep 
disturbance in metastatic breast cancer patients, a symptom rated as highly important, the 
effect of sleep disturbance on other symptoms in the cluster—including anxiety and 
depressive symptoms—may dissipate.  However, when a sample of cancer patients has 
heterogeneous treatment priorities, these individual differences may lessen the effects of 
one treatment approach—such as CBT-I—on adherence to treatment recommendations 
and severity of related symptoms.  Therefore, single-subject designs or micro-randomized 
trials may provide an avenue for tailoring treatment to patients’ priorities while still 
maintaining experimental control.  
4.5   Limitations, Strengths, and Future Directions 
 Limitations of the current study should be noted.  With the exception of medical 
record data (i.e., age, diagnosis date, and cancer treatment history), all measures were 
self-report.  Self-reported data are vulnerable to biases including a desire to comply with 
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study expectations, social desirability, or an inability to accurately remember symptoms 
and their severity.  Inaccurate recall may have been a particular issue for this study 
because participants with cognitive complaints may have had more difficulty 
remembering the severity of their symptoms over the last one or two weeks.  However, 
many of these symptoms (e.g., pain) are inherently subjective experiences with self-
report as the primary method of assessment. 
 Another limitation is the use of multiple brief symptom assessments.  Although 
the measures have shown adequate reliability and validity, they may not fully capture the 
complexity of symptom constructs.  The use of multiple assessments resulting in a 45-
minute interview may also be overly burdensome for some patients with metastatic 
cancer.  However, interviews of this length have been performed successfully in prior 
research with metastatic breast cancer patients (Mosher & DuHamel, 2012).  
Furthermore, the length of the interview in the current study seemed to be feasible 
considering the high consent and completion rates (see Figure 4).  
 Our sample was primarily Caucasian and only included women recruited from 
one academic cancer center in the Midwest; thus our findings may not generalize to men 
with the same disease, ethnic minorities, or patients in other geographical or institutional 
settings.  Also, participants in our study had attained some college education on average 
(M = 15.02 years of education), although a wide range of education was reported (11-20 
years).  Regarding socio-economic status, one-fifth of the sample reported the lowest 
(i.e., $0-$30,999 per year) and highest (i.e., $100,000 +) income levels, and the most 
common income category was middle class ($51,000 - $99,999).  Therefore, although 
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this sample had a range of education and income levels, our findings may not generalize 
to patients of lower socioeconomic status. 
 Another potential limitation is the use of cluster analysis, a data driven, 
exploratory analytical approach; therefore, findings warrant replication.  However, an 
exploratory approach was appropriate considering the paucity of research on symptom 
clusters in metastatic breast cancer patients.  The analytic approach was also strengthened 
by using weighted average linkage as the clustering method rather than Ward’s method; 
Ward’s method forces clusters to be similar sizes and is sensitive to outliers (McQuitty, 
1966; Miaskowski et al., 2006).   
The cross-sectional nature of our study precludes examining change in symptom 
clusters or patient ratings of symptom importance, both of which may be temporally 
unstable.  Furthermore, although we collected information on cancer treatments, 
unexamined factors such as contact with a physician or adherence to medications may 
also be related to symptom clusters and importance.   
 Despite limitations, the current study also has several strengths.  The study sample 
consisted of metastatic breast cancer patients, a population which has received scarce 
research attention despite their high symptom burden and increased longevity.  
Additionally, the majority of self-report measures have demonstrated good validity and 
reliability.  There was also a considerably high response rate, as 87% (83/95) of patients 
contacted by phone consented to participate, and 96% (80/83) of consenting participants 
completed the assessment. 
 Future research on symptom clusters and symptom importance in cancer 
populations may build upon the current findings.  Longitudinal designs may track 
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symptom clusters and symptom importance to test the temporal stability of these 
constructs.  Future designs may also include objective measurements of symptoms when 
possible (e.g., sleep disturbance) or supplement self-report measures with observer (e.g., 
physician, caregiver) ratings.  Treatment priorities may also be assessed with other 
methods such as asking participants to rank order their symptoms by importance, and 
differences among such measurement methods may be explored.  A mixed-methods 
approach to this research may provide quantitative information about symptoms rank-
ordered by importance, and qualitative information about participants reasoning for those 
rankings.  Finally, future research may benefit from assessing other disease and quality-
of-life factors along with symptom clusters and importance to generate a model of factors 
influencing symptom relationships and patients’ treatment priorities. Such models may 
change at different points in the illness trajectory (e.g., diagnosis, treatment, end of life). 
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CHAPTER 5. CONCLUSION 
 Many breast cancer patients experience cognitive symptoms related to cancer and 
its treatment, but our current understanding of cognitive symptoms in metastatic breast 
cancer patients is limited.  The present study addresses gaps in our understanding of 
symptoms co-occurring with cognitive complaints in this population and the patient-rated 
importance of cognitive complaints as compared to other symptoms.  In this sample, 
cognitive complaints clustered with anxiety, depressive symptoms, sleep problems, and 
fatigue.  Additionally, cognitive symptoms were rated as significantly more important 
than anxiety, depressive symptoms, neuropathy, swelling, nausea, and hot flashes, and 
importance ratings did not differ among cognitive symptoms, pain, fatigue, and sleep 
problems.  Although pain did not cluster with cognitive symptoms, fatigue, and sleep 
problems, it was still rated as equally important.  Although anxiety and depressive 
symptoms clustered with cognitive symptoms, fatigue, and sleep problems, they were 
both rated as significantly less important.  However, the differences in importance ratings 
were small.  Future research may provide a more comprehensive understanding of 
symptom experiences and treatment priorities by using alternative and mixed methods to 
assess treatment priorities, exploring how symptom clusters and symptom importance 
may change over time, and developing a model of symptom experiences with other 
important outcomes such as patient adherence to interventions.  Developing patient-
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centered approaches to symptom management based on symptom severity and treatment 
priorities has the potential to impact patients’ quality of life as well as improve health 
care quality and patients’ adherence to treatment recommendations. 
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Appendix A Measures 
Cognitive Screening for Patients 
I would like to ask you some questions that ask you to use your memory. I am going to 
name three objects. Please wait until I say all three words, then repeat them. Remember 
what they are because I am going to ask you to name them again in a few minutes. Please 
repeat these words for me: APPLE—TABLE—PENNY. (Interviewer may repeat words 
3 times if necessary but repetition not scored.) 
Did patient correctly repeat all three words? Yes No 
   
 Incorrect Correct 
1. What year is this? 0 1 
2. What month is this? 0 1 
3. What day of the week? 0 1 
What were the three objects I asked you to remember?   
4. Apple = 0 1 
5. Table = 0 1 
6. Penny = 0 1 
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Demographic Information 
1. What race or ethnicity to you consider yourself to be? 
  
1 = non-Hispanic White 
2 = African American/Black 
3 = Asian 
4 = Hispanic 
5 = Native Hawaiian or other Pacific Islander 
6 = American Indian/Alaskan Native 
7 = Other 
 
2. What was the last grade you completed in school? 
 
 
3. What is your marital status? 
 
1 = Married 
2 = Living with partner 
3 = Separated 
4 = Single 
5 = Divorced 
6 = Widowed 
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4. Thinking about your yearly household income, before taxes, is it $21,000 or 
higher? 
       1 = $0 - $10,999 
if no, Is it $11,000 or higher?    2 = $11,000 - $20,999 
if yes, Is it $31,000 or higher?    3 = $21,000 - $30,999 
if yes, Is it $41,000 or higher?   4 = $31,000 - $50,999 
if yes, Is it $51,000 or higher?   5 = $50,000 - $99,999 
if yes, Is it $100,000 or more?   6 = $100,000 + 
 
5. What is your current employment status? 
 
1 = Employed full-time 
2 = Employed part-time 
3 = Student 
4 = Homemaker 
5 = Retired 
6 = Unemployed, looking for paid work 
7 = Unemployed due to disability 
8 = Other 
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Information Collected from Medical Record 
(1) Age: _____ 
 
(2) Date(s) of Breast Cancer Diagnosis and Disease Stage at Diagnosis:  
 
a. ____/____/_____;  Disease Stage  (circle one): 0     1     2     3     4 
 
b. ____/____/_____;  Disease Stage  (circle one): 0     1     2     3     4 
 
c. ____/____/_____;  Disease Stage  (circle one): 0     1     2     3     4 
 
 
Treatments for Breast Cancer (check all that have been received):   1 = yes, 0 = no 
  
 Mastectomy 
 Lumpectomy 
 Surgery to remove metastases 
 Bilateral oophorectomy 
 Other surgery (specify):____________ 
 Chemotherapy 
 Radiation   
      Did the patient receive radiation to the brain?  ___yes    ___no 
 Targeted therapy (e.g., trastuzumab, bevacizumab) 
 Hormonal therapy (e.g., Tamoxifen) 
 Bisphosphonate/s 
 Other (please specify): ______________________________  
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Medical Conditions 
I am going to read you a list of chronic health problems that some people have. Please tell 
me if a doctor or another health care worker has diagnosed you with or treated you for 
one of the following medical problems in the past 3 years.  
 
No = 0 Yes = 1 Don’t know or refused to 
answer = 99 
 
 
1. In the past 3 years, have you been diagnosed or treated for asthma, emphysema, 
or chronic bronchitis 
2. In the past 3 years, have you been diagnosed or treated for high blood pressure or 
hypertension 
3. High blood sugar or diabetes 
4. Arthritis or rheumatism (inflammation of the joints) 
5. Angina, heart failure, or other types of heart disease 
6. Stroke, seizures, Parkinson’s disease, or another neurological condition 
7. Liver disease 
8. Kidney or renal disease 
9.   Cancer other than breast cancer or skin cancer 
 if Yes [List types: ________________________________] 
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PROMIS Applied Cognition – General Concerns 
In the past 7 days… 
 Never Rarely 
(Once) 
Sometimes 
(Two or 
three times) 
Often 
(About 
once a day) 
Very Often 
(Several 
times a day) 
1. My thinking has 
been slow… 
5 4 3 2 1 
2. It has seemed 
like my brain was 
not working as 
well as usual… 
5 4 3 2 1 
3. I have had to 
work harder than 
usual to keep track 
of what I was 
doing… 
5 4 3 2 1 
4. I have had 
trouble shifting 
back and forth 
between different 
activities that 
require thinking… 
5 4 3 2 1 
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PROMIS Emotional Distress – Depression 
In the past 7 days… 
 Never Rarely Sometimes Often Always 
1. I felt 
worthless… 
1 2 3 4 5 
2. I felt 
helpless… 
1 2 3 4 5 
3. I felt 
depressed… 
1 2 3 4 5 
4. I felt 
hopeless… 
1 2 3 4 5 
 
PROMIS Emotional Distress – Anxiety 
In the past 7 days… 
 Never Rarely Sometimes Often Always 
1. I felt 
fearful… 
1 2 3 4 5 
2. I found it 
hard to focus 
on anything 
other than my 
anxiety… 
1 2 3 4 5 
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3. My worries 
overwhelmed 
me… 
1 2 3 4 5 
4. I felt 
uneasy… 
1 2 3 4 5 
 
PROMIS Fatigue 
During the past 7 days… 
 Not at all A little bit Somewhat  Quite a bit Very much 
1. I feel 
fatigued… 
1 2 3 4 5 
2. I have 
trouble 
starting 
things 
because I am 
tired… 
1 2 3 4 5 
 
In the past 7 days… 
 Not at all A little bit Somewhat  Quite a bit Very much 
3. How run-
down did 
1 2 3 4 5 
100 
 
 
 
you feel on 
average? 
4. How 
fatigued 
were you on 
average? 
1 2 3 4 5 
 
PROMIS Sleep Disturbance 
In the past 7 days… 
1. My sleep quality was… 
Very poor = 1  Poor = 2 Fair = 3 Good = 4 Very Good = 5 
 Not at all A little bit Somewhat Quite a bit Very much 
2. My sleep 
was 
refreshing… 
1 2 3 4 5 
3. I had a 
problem with 
my sleep… 
1 2 3 4 5 
4. I had 
difficulty 
falling 
asleep… 
1 2 3 4 5 
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PROMIS Pain Intensity 
In the past 7 days… 
 No pain Mild  Moderate Severe Very Severe 
1. How 
intense was 
your pain at 
its worst? 
1 2 3 4 5 
2. How 
intense was 
your 
average 
pain? 
1 2 3 4 5 
3. What is 
your level of 
pain right 
now? 
1 2 3 4 5 
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MSAS Selected items and Carpenter et al. (1998) 
 
1. Have you had nausea in the past week?   
 
No = 0, skip to question 2.  Yes = 1  
 
how often did you have it?  
 
Rarely = 1 Occasionally = 2 Frequently = 3 Almost constantly = 4 
 
 how severe was it usually?  
  
Slight = 1 Moderate = 2 Severe = 3 Very Severe = 4 
     
 how much did it distress or bother you?  
   
Not at all = 0 A little bit = 1 Somewhat = 2 Quite a bit = 3 Very much = 4 
 
2. Have you had numbness/tingling in your hands/feet in the past week? 
 
No = 0, skip to question 3.  Yes = 1 
 
how often did you have it?  
 
Rarely = 1 Occasionally = 2 Frequently = 3 Almost constantly = 4 
 
 how severe was it usually?  
  
Slight = 1 Moderate = 2 Severe = 3 Very Severe =4 
     
 how much did it distress or bother you?  
   
Not at all = 0 A little bit = 1 Somewhat = 2 Quite a bit = 3 Very much = 4 
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3. Have you had swelling of arms or legs in the past week? 
 
No = 0, skip to question 4.  Yes = 1 
 
how severe was it usually?  
  
Slight = 1 Moderate = 2 Severe = 3 Very Severe = 4 
     
 how much did it distress or bother you?  
   
Not at all = 0 A little bit = 1 Somewhat = 2 Quite a bit = 3 Very much = 4 
 
4. Have you experienced hot flashes in the past 2 weeks?  
 
No = 0, skip to next measure.  Yes = 1 
 
how severe were they usually?  
 
Not at all = 0 Slightly = 1 Moderately = 2 Quite a bit = 3 Extremely = 4 
 
how much did the hot flashes bother you on a scale from 0 to 10, 0 being not at all 
bothered and 10 being extremely bothered?  
 
   0 1 2 3 4 5 6 7 8 9 10 
Not at all                Extremely 
bothered               bothered 
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PCOQ-Revised for metastatic breast cancer 
 
Many people experience pain, fatigue (i.e. feeling tired), anxiety, and other symptoms as 
a result of their medical condition. We would like to understand how you have been 
impacted in each of these areas.  We would also like to learn more about what you want 
your treatment to do for you. 
 
First, we would like to know your USUAL levels of pain, fatigue, anxiety, and other 
symptoms.  
 
On a scale of 0 (none) to 10 (worst imaginable) please indicate your usual level (during 
the past week) of…  
 
Pain     _____  Swelling of arms or legs _____ 
 
Fatigue (or tiredness)   _____  Nausea   _____ 
  
Anxiety    _____  Hot flashes   _____ 
 
Sadness    _____  Sleep problems  _____ 
 
Numbness/tingling in hands/feet _____  Attention/thinking/memory _____ 
problems          
 
Patients understandably want their treatment to result in desired or ideal outcomes. 
Unfortunately, available treatments do not always produce desired outcomes. Therefore, 
it is important for us to understand what treatment outcomes you would consider 
sucessful.  
 
On a scale of 0 (none) to 10 (worst imaginable) please indicate the level each of these 
areas would have to be at for you to consider treatment SUCCESSFUL. 
 
Pain     _____  Swelling of arms or legs _____ 
 
Fatigue (or tiredness)   _____  Nausea   _____ 
  
Anxiety    _____  Hot flashes   _____ 
 
Sadness    _____  Sleep problems  _____ 
 
Numbness/tingling in hands/feet _____  Attention/thinking/memory _____ 
problems               
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Now, we would like to know what you EXPECT your treatment to do for you. 
 
On a scale of 0 (none) to 10 (worst imaginable) please indicate the levels you expect 
following treatment. 
 
Pain     _____  Swelling of arms or legs _____ 
 
Fatigue (or tiredness)   _____  Nausea   _____ 
  
Anxiety    _____  Hot flashes   _____ 
 
Sadness    _____  Sleep problems  _____ 
 
Numbness/tingling in hands/feet _____  Attention/thinking/memory _____ 
problems               
Other (please specify)___________  _____ 
Say, “Is there any other symptom that you have experienced? What level of this symptom 
do you expect following treatment?” 
 
Finally, we would like to understand how IMPORTANT it is for you to see improvement 
in your pain, fatigue, anxiety, and other symptoms following treatment. 
 
On a scale of 0 (not at all important) to 10 (most important) please indicate how 
important it is for you to see improvement in your… 
 
Pain     _____  Swelling of arms or legs _____ 
 
Fatigue (or tiredness)   _____  Nausea   _____ 
  
Anxiety    _____  Hot flashes   _____ 
 
Sadness    _____  Sleep problems  _____ 
 
Numbness/tingling in hands/feet _____  Attention/thinking/memory _____ 
problems               
  
106 
 
 
 
Appendix B Figures 
 
 
Figure 1.  Model of Interacting Factors Involved in Cognitive Change Associated with 
Cancer and Its Treatment. 
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Figure 2.  Trajectories of Cognitive Change over Time. Adapted from Ahles, T. A., Root, 
J. C., & Ryan, E. L. (2012). Cancer- and cancer treatment-associated cognitive change: An 
update on the state of the science. Journal of Clinical Oncology, 30, 3675-3686. doi: 
10.1200/jco.2012.43.0116. 
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Figure 3. Hypothesized Dendrogram of a Symptom Cluster Involving Cognitive 
Complaints in Metastatic Breast Cancer Patients. 
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Figure 4.  Flow Chart of Study Procedures. 
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Figure 5.  Cluster Dendrogram.  One value each for swelling, anxiety, and depressive 
symptoms was Winsorized prior to this analysis. 
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Figure 6.  Cluster Dendrogram with Clusters Boxed.  One value each for swelling, 
anxiety, and depressive symptoms was Winsorized prior to this analysis. 
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Figure 7.  Cluster Dendrogram using non-Winsorized Variables. 
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Figure 8.  Cluster Dendrogram using non-Winsorized Variables with Clusters Boxed. 
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Figure 9.  Bar Graph of Mean Symptom Importance Ratings with 95% Confidence 
Interval Error Bars.  One value for fatigue importance was Winsorized prior to this 
analysis. 
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Appendix C   Tables 
 
Table 1.  Cognitive Domains found to be Impaired among Breast Cancer Survivors in 
Meta-Analyses.  *Found to be a significant deficit.  Findings in red text are inconsistent 
with findings in the most recent meta-analysis.  N/A = domain not assessed in the meta-
analysis. 
 
 
 
 
 
Ono et al. (2015) Jim et al. (2012) Stewart et al. 
(2006) 
Jansen et al. 
(2005) 
Falleti et al. 
(2005) 
Processing 
speed* 
Processing speed Processing speed Processing 
speed* 
N/A 
Executive 
function* 
Executive 
function 
Executive 
function* 
Executive 
function* 
Executive 
function 
Attention* Attention Attention Attention Attention 
Motor function* Motor function Motor function* Motor function Motor function 
Short-term 
memory* 
N/A Short-term 
memory* 
N/A N/A 
Language Language* Language* Language Language* 
Long-term 
memory 
N/A Long-term 
memory* 
N/A N/A 
Visuospatial 
function 
Visuospatial 
function* 
Visuospatial 
function 
Visuospatial 
function 
Visuospatial 
function* 
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Table 2.  Participant Characteristics (N = 80).  SD = standard deviation.  aAfrican 
American/Black, Hispanic, and other.  bHistory of bladder cancer 
Characteristic  
Age  
    Mean (SD) 
    Range 
 
      55.5 (11.26)  
32-80 
Years of education  
   Mean (SD) 
   Range 
 
15.03 (2.42) 
11-20 
Years since the stage IV breast cancer diagnosis  
   Mean (SD) 
   Range 
 
   3.93 (3.64) 
.21-19.46 
Ethnicity, no. (%)  
    Non-Hispanic White          73 (91.3%) 
    Other ethnicitya          7 (8.8%) 
Married or partnered, no. (%)       53 (66.3)  
Employed, no. (%)       24 (30.0) 
Household Income, no. (%)  
    $0 - $30,999       17 (21.8) 
    $31,000 - $50,999       18 (23.1) 
    $51,000 - $99,999       26 (33.3) 
    $100,000 +       17 (21.8) 
Cancer treatment history, no. (%)  
    Chemotherapy       69 (86.3) 
    Hormonal therapy       68 (85.0) 
    Mastectomy       53 (66.3) 
    Radiation       52 (65.0) 
    Targeted therapy       36 (45.0) 
    Lumpectomy       17 (21.3) 
Medical comorbidities  
    Hypertension       26 (32.5) 
    Arthritis       20 (25.0) 
    Diabetes       11 (13.8) 
    Asthma, emphysema, or chronic bronchitis         9 (11.3) 
    Stroke or other neurological condition       3 (3.8) 
    Heart disease       2 (2.5) 
    Liver disease       2 (2.5) 
    Kidney disease       2 (2.5) 
    Other cancersb       1 (1.3) 
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Table 3.  Winsorization of Main Study Variable Outliers.  aMemorial Symptom 
Assessment Scale (MSAS) average score of symptom severity and distress.   
bPROMIS measure total score.  cPatient-Centered Outcomes Questionnaire (PCOQ) 
symptom importance score. 
 Variable value 
Variable Original Winsorized 
Swellinga 4 3 
Anxietyb 17 16 
Depressive symptomsc 20 16 
Fatigue importanced 0 2 
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Table 4.  Descriptive Statistics and Normality Estimates for Main Study Variables.  SD = 
standard deviation. 
    Normality estimate  
Variable Mean SD Range Skewness Kurtosis Cronbach’s α 
Nausea   0.63 0.91 0 – 3.00  1.12 -0.07 0.95 
Neuropathy   1.13 1.19 0 – 3.67  0.39 -1.44 0.89 
Swelling   0.46 0.87 0 – 3.00  1.65  1.28 0.91 
Hot flashes   1.64 1.92 0 – 7.00  0.75 -0.66 0.75 
Pain   6.60 2.65 3 – 13  0.26 -0.76 0.83 
Fatigue 11.39 4.31 4 – 20  0.20 -0.97 0.92 
Sleep problems 11.10 3.90 4 – 20  0.48 -0.43 0.84 
Cognitive problems 11.43 5.11 4 – 20  0.26 -1.06 0.95 
Anxiety   7.33 3.14 4 – 16  0.51 -0.85 0.86 
Depressive symptoms   6.65 3.20 4 – 16  1.39  1.19 0.90 
Pain importance   7.79 2.83 0 – 10 -1.61  1.83  
Fatigue importance   7.96 2.21 2 – 10 -1.48  1.53  
Anxiety importance   6.58 3.53 0 – 10 -0.89 -0.61  
Sadness importance   6.36 3.48 0 – 10 -0.78 -0.72  
Neuropathy importance   5.71 3.57 0 – 10  -0.47 -1.21  
Swelling importance   4.93 4.06 0 – 10 -0.07 -1.72  
Nausea importance   6.25 4.01 0 – 10 -0.64 -1.31  
Hot flashes importance   5.41 3.65 0 – 10 -0.34 -1.34  
Sleep importance   7.23 3.04 0 – 10 -1.11  0.07  
Thinking problems 
importance   7.69 3.14 0 – 10  -1.52  1.10  
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Table 5.  T Score Means and Standard Deviations for PROMIS-Measured Symptoms.  
aScores from the current sample were calibrated based on scores obtained in PROMIS 
calibration samples.  The cancer calibration sample consisted of 1,754 participants that 
completed PROMIS measures on a web-based polling platform and self-reported a cancer 
diagnosis (Cella et al., 2010).  The cancer stage of participants in the cancer population 
sample has not been reported.  The wave 1 general population sample consisted of 21,133 
participants (including clinical samples such as those who reported cancer) who were 
52% female with a mean age of 50 years, and this sample has been shown to be 
representative of the general U.S. population (Cella et al., 2010; Liu et al., 2010).  Mean 
T score of 50 and standard deviation of 10 reflect the mean and standard deviation 
obtained in calibration samples.    
 Cancer calibrationa   Wave 1 calibrationa  
Variable Mean SD  Mean SD 
Anxiety 51.27 8.82    
Cognitive concerns 41.16 9.97    
Depressive symptoms 50.42 8.45    
Fatigue 55.39 9.73    
Pain    43.81 8.58 
Sleep disturbance    53.07 3.35 
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Table 6.  Repeated-Measures ANOVA on Symptom Importance Ratings for Symptoms 
Assessed with the Modified Patient-Centered Outcomes Questionnaire (PCOQ).  adf 
corrected with Greenhouse-Geisser ε for violation of sphericity assumption.  
Source SS dfa MS F η2 p 
Symptom   801.75     5.80 138.30 13.77 0.15 < .001 
Error 4600.66 457.97   10.05       
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Table 7.  Simple Contrasts Comparing the Importance of Thinking Problems to the 
Importance of Other Symptoms.  SE = standard error. *p < 0.05. 
 Symptom (I) Symptom (J) 
Mean 
Difference 
(I – J)  SE p 
95% Confidence 
Interval  
Lower 
Bound 
Upper 
Bound 
Thinking 
problems 
Pain -0.10 0.41 .810 -0.92 0.72 
Fatigue -0.28 0.28 .328 -0.83 0.28 
Anxiety  1.11* 0.37 .004  0.37 1.85 
Sadness  1.33* 0.33 .000  0.67 1.98 
Neuropathy  1.98* 0.43 .000  1.12 2.83 
Swelling  2.76* 0.46 .000  1.84 3.68 
Nausea  1.44* 0.49 .005  0.46 2.42 
Hot flashes  2.28* 0.36 .000  1.57 2.98 
Sleep 
problems  0.46 0.26 .076 -0.05 0.97 
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Appendix D   Syntax 
R Syntax – For Cluster Analysis 
install.packages("cluster") 
library(cluster) 
thesisdata = read.csv(file.choose(), header = TRUE) 
#remove non-numeric column 
thesisdata.use=thesisdata[, -c(1)] 
thesisdata.use 
#calculate the euclidean distance matrix 
distance=dist(thesisdata.use, method="euclidean") 
#calculate squared euclidean distance 
d.sqeuc=distance^2  
#run the cluster analysis 
thesisdata.hclust=hclust(d.sqeuc, method="mcquitty") 
#create dendrogram of cluster analysis 
plot(thesisdata.hclust) 
plot(thesisdata.hclust,labels=thesisdata$Symptom) 
#cut the winsorized one at 110 and non-winsorized one at 120 
rect.hclust(hclust(d.sqeuc, method="mcquitty"),h=110) 
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SPSS Syntax – For Repeated-Measures ANOVA 
 
GLM PCOQ4pain PCOQ4fatig PCOQ4anx PCOQ4sad PCOQ4numb PCOQ4swell 
PCOQ4naus PCOQ4hotf PCOQ4sleep  
    PCOQ4cog 
  /WSFACTOR=symptom 10 Polynomial  
  /MEASURE=importance  
  /METHOD=SSTYPE(3) 
  /EMMEANS=TABLES(symptom) COMPARE ADJ(LSD) 
  /PRINT=DESCRIPTIVE  
  /CRITERIA=ALPHA(.05) 
  /WSDESIGN=symptom. 
 
DATASET ACTIVATE DataSet1. 
GRAPH 
  /BAR(SIMPLE)=MEAN(PCOQ4pain) MEAN(PCOQ4fatig) MEAN(PCOQ4anx) 
MEAN(PCOQ4sad) MEAN(PCOQ4numb) MEAN(PCOQ4swell)  
    MEAN(PCOQ4naus) MEAN(PCOQ4hotf) MEAN(PCOQ4sleep) MEAN(PCOQ4cog)  
  /MISSING=LISTWISE 
  /INTERVAL CI(95.0). 
 
